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1 Introduction 
Cancer or malignant neoplasm is a term used for a group of diseases character-
ised by progressively uncontrolled growth of cells and spread to other organs in 
the body. A delayed diagnosis makes a treatment difficult so that the disease can 
become life-threatening.  
In general, two types of tumours may be distinguished: benign tumours and ma-
lign tumours. Both are abnormal tissue masses whose growth is increased and 
uncoordinated with the healthy tissue, thus proceeding autonomously. Benign 
tumours are not classified as cancer because they do not have the ability to mi-
grate and build new tumours in distant organs of the body. But they can still ac-
quire these capabilities which allow them to become malign tumours.  
Malignant tumours display three key features: infiltration, destruction and metas-
tasis. Infiltration is the process where the uncontrolled cells invade through the 
basal membrane in order to reach a blood vessel. For this purpose it destroys 
nearby cells and matrix material. Metastasis describes the process of migration 
and attachment to a new environment (other organ) that lead to daughter cells to 
make new colonies. How the fate of a cell changes to be malignant, is discussed 
more detailed later on (Schulte-Hermann 2009, Weinberg 2007). 
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1.1 Epidemiology of Cancer 
Malignant neoplasms are the second most common cause of death especially in 
Western Europe and other developed countries (WHO). 
 
  
Figure 1-1 distribution of death causes worldwide (source: UCATLAS 2000) 
Figure 1-2 incidence and mortality rates of cancer 
in different continental regions between men and women (source: WHO) 
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Incidence and mortality rates are high in New Zealand, Northern America and 
Western as well as Northern Europe while there African regions have lower inci-
dence rates. (WHO, Dobrucalı 2011) 
Every year more than 1.2 million people are diagnosed with cancer and in 2008, 
cancer accounted for about 7.6 million deaths. According to the WHO, tobacco is 
a major cancer risk factor together with alcohol use, wrong diet and a lack of 
physical activity. By the year 2030 the WHO expects cancer deaths to have risen 
to above 11 million. 
 
 
In Austria more than one third of deaths were caused by cancer in 2010 (Statistik 
Austria 2010). The risk of dying from cancer is the lowest for people in their twen-
ties and increases with 30 years of age. According to the data of last year, people 
in their 50s have the highest risk. 
Figure 1-3 top 10 causes of death  
in high income countries (source: WHO 2008) 
Figure 1-4 percent of death caused by listed reasons in 2010 for Austria (source: Statistik Austria) 
in Austria 
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Figure 1-5 incidence (left) and death rates (right) of various cancer types in Austria (up)  
and worldwide (lower graphics) (source: WHO GloboCan 2008) 
Austria 
incidences      cancer deaths 
worldwide 
1.2 Epidemiology of Colorectal Cancer 
Among the different cancer types lung cancer takes the first place worldwide in 
both incidence and death rates, followed by stomach, liver and colorectal cancer 
(CRC). Every year more than 1.2 Million people are diagnosed with CRC which 
represents 9.8% of all cancers. When we compare incidence and mortality rates 
between male and female, we see prostate cancer with the highest incidence 
rates for men while for women it is the breast (WHO GloboCan 2008). 
 
In Austria colorectal cancer is the second cause of cancer deaths. More than 
35,000 people develop cancer annually - 12.6% of them are diagnosed with CRC.  
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1.3 Risk factors of CRC 
CRC development depends on the number of polyps in the colon which can form 
due to many risk factors including age, family history and immunologic state. In 
the following, some environmental and hereditary factors will be discussed. 
1.3.1 Dietary factors 
The frequency of CRC shows differences between people living in distinct geo-
graphic regions. In Australia, New Zealand, Northern America and Middle Europe 
the incidence is high while people living in Asia and Southern America are less 
likely to get CRC. This can be explained by the different dietary and environmen-
tal factors (partly based on the particular culture) of locals. 
In 2010, Stefani et al. have shown in their factor analysis made in Uruguay (South 
America) that Western life style (“Western pattern”) was associated with an in-
creased risk of colon cancer while people having a prudent diet were inversely 
associated with rectal cancer. The prudent pattern was the factor that showed 
“white meat, dairy foods, desserts, total vegetables, and total fruits” while they la-
belled “high loadings for red meat, total grains, and all tubers” and “high negative 
loadings on white meat and raw vegetables” as the Western pattern. 
This was also proven by the observation that people migrating from low risk to 
high risk regions are more likely to get CRC. To name one, it is known that Japa-
nese immigrants in U.S. have developed higher risk of CRC within 2 generations 
and surpassed the risk level of Native Americans than Japanese living in their 
countries (Flood et al. 2000).  
Figure 1-6 fat intake and risk of CRC in various countries between the years 1977-1979 
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1.3.2 Familial Adenomatous Polyposis 
Familial adenomatous polyposis coli (FAP) is a hereditary colon cancer syndrom 
that is transmitted in an autosomal dominant manner. It results from a mutation or 
deletion in the APC gene lying on the long arm of the fifth chromosome (5q). The 
frequency is about one per 10,000 and leads to adenomas in teenage years 
(Menko 1993). At least 100 polyps are formed in the colon at young ages - one of 
which will surely develop into a carcinoma.  
APC encodes for a tumour-suppressor protein and is mostly known for its role in 
the degradation of a protein called β-catenin (Wnt-pathway, detailed description 
in chapter 1.7.1). Loss of APC results in increased levels of free β-catenin leading 
to uncontrolled cell expansion. APC also interacts with the microtubules, so that 
in its absence results in defects of the mitotic spindle arise that can lead to chro-
mosome abnormalities.  
1.3.3 Hereditary Non-Polyposis Colorectal Cancer 
Abbreviated as HNPCC, this type of hereditary colon cancer results from the loss 
of mismatch repair genes (MMR genes) and leads to an accelerated cancer de-
velopment (in 1-2 years). The MMR system is a group of proteins that monitor 
any mistakes made during DNA replication. Recognition of mistakes, the affected 
replicon is removed and remade. When these proteins are missing or mutated, 
mutations accumulate much more rapidly and pass on to the next generation of 
cells during mitosis. 
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Figure 1-7 concept of initation and promotion 
(own drawing, concept from Prof. Schulte-Hermann) 
initiation promotion (selection) progression 
pre-neoplastic 
cell clones 
benign tumour malign tumour 
1.4 How does cancer develop?  
Back in the 40’s, the concept of initiation and promotion emerged. It was based 
on an experiment where a tumorigenic substance was applied exogenously on 
the skin of mice. This substance is known as an initiator of cancer and fails to 
cause tumours unless the dosage is high enough. Additional administration of 
agents triggering inflammation acts synergistically by creating a growth ad-
vantage for initiated cells, thus promoting tumour development. The sequence 
and interval of administration was quite important: mice did not develop any can-
cer when cancer initiating agents were applied after the promoters or when 
intervals between promoter applications were too long. However, even when 
considerable time had passed after initiation, appliance of promoting substances 
still led to cancer. This means that initiation is an irreversible step, affecting the 
genes, while promotion is just a trigger. 
Tumour development happens in many steps (Figure 1-7) and begins with a 
slight change in one single cell which can be seen as the initiation step described 
above. Daughter cells gain proliferation advantage and accumulation of genetic 
alterations results in hyperplasia. In the next cell division, a dysplasia with a pro-
liferative tendency is born. With more mutations the cells speed up their cell-cycle 
which gives new daughter cells the chance to escape from home through invad-
ing basal layer. This is the first step of invasiveness and allows the cells to 
penetrate into blood vessels to transport daughter cells. The process is called 
epithelial-to-mesenchymal transition (EMT) where the cell decreases production 
of adherence proteins and boosts expression of proteins that facilitate free 
movement (Schulte-Hermann). 
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1.5 Cancer on the cellular level 
Eukaryotic cells of multicellular organisms are regulated by numerous intra- and 
extracellular signalling pathways. Within a normal tissue in an adult organism 
multiple anti-proliferative signals are produced to maintain the cells in a quiescent 
state thus maintaining tissue homeostasis. Specific mitogenic growth signals are 
required to induce cell proliferation. Proliferation is limited by an intrinsic cell-
autonomous program, and -after a defined number of divisions- cells stop grow-
ing and become senescent.  
Also tumour cells progressively lose their sensitivity for induction of apoptosis. 
Each cell has sensors (death-receptors of TNF-receptor protein family and regu-
lators of mitochondrial-permeability) that monitor the extracellular and intracellular 
environment. In case of damage, like a double strand break in the DNA, they can 
activate effector molecules which initiate apoptotic mechanisms and lead to cell 
death. The immune system has specialised cells which can promote apoptosis 
and remove the dead cells by phagocytosis. 
These intra- and intercellular control mechanisms have to be overcome to pro-
duce a cancer cell so it can survive and proliferate.  
  
Figure 1-8 nine characteristics of a cancer cell  
(source: Hanahan and Weinberg, 2011) 
 9 
Douglas Hanahan and Robert Weinberg have postulated nine characteristics of 
malignant cells (Figure 1-8) which will be shortly reviewed and important actors 
highlighted in the following passages. 
1.5.1 Production of growth signals 
As described earlier normal cells are kept in a steady homeostatic state between 
growth signals and anti-growth signals by other cells in the environment. The 
former are called growth factors and include the family of epithelial growth factors 
(EGF), the platelet-derived growth factors (PDGF) and the fibroblast growth factor 
family (FGF) as well as the tumour growth factors (TGFs) and vascular endotheli-
al growth factors (VEGF and numerous others). These extracellular proteins act 
through binding to receptors on the surface of a cell which activate intracellular 
proteins by phosphorylation in a signalling cascade and lead to the expression of 
different target genes. 
With time, cancer cells can acquire the ability to produce the growth factors to 
stimulate their own proliferation (autocrine stimulation). Alternatively, they may 
induce other cells in their environment to produce growth factors. Other strategies 
can also be mutation(s) in the receptor molecule that fires permanently and inde-
pendently from ligand binding. It is known that B-Raf has an activating-mutation 
(V600E) in 40% of the human melanomas (Maurer et al. 2011, Davies and Sam-
uels 2010, Baccarini 2005). Evidence of alterations downstream of the MAPK 
pathway having wildtype B-Raf (and N-Ras) also exist (Curtin et al. 2005). Alt-
hough rare, chromosomal translocations that lead to fusion genes with B-Raf or 
C-Raf have been described to have a pro-proliferative role and support migration 
in prostate cancer, gastric cancer and melanoma (Maurer et al. 2011, Baccarini 
2005). 
1.5.2 Loosing sensitivity to anti-growth signals 
It is not sufficient to up-regulate growth promoting factors because there are 
counteracting mechanisms involving tumour suppressor proteins. Therefore can-
cer cells deactivate these proteins by different mechanisms. The retinoblastoma-
associated protein (Rb) is one example.  
Transcription factors (TFs) that are important during the G1 phase of the cell cy-
cle have to bind to DNA in order to activate transcription. These are bound to the 
Rb-protein and phosphorylation of this protein is required to release the TFs and 
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permit their binding to respective DNA sequences and start mitosis. Any critical 
mutation of Rb leading to a release of TFs provides the cancer cell to proceed the 
cell cycle. The Rb gene is inactivated in all retinoblastomas, in 60% of osteosar-
comas and 30% of breast cancers as well as bladder carcinomas. (Hanahan and 
Weinberg 2011) 
1.5.3 Replication ad infinitum 
Healthy cells have an intrinsic switch that tells them when to stop dividing. When 
the so-called “Hayflick limit” is reached, cells undergo senescence – a state 
growth arrest that ultimately leads to cell death.  
Shortly reviewed, telomeres are the chromosome ends with various proteins that 
form the telomeric loop in order to protect these from degradation. They consist of 
many repeats of a hexanucleotide with a length of 10kb (in humans). Because no 
RNA-primer can attach for the synthesis of the Okazaki fragments at the chromo-
some ends, part of the continuous strand remains unreplicated, shortening the 
chromosome with every replication cycle until they are too short for binding of the 
protective proteins. If this happens, the open DNA end is recognised as DNA-
damage and the cell cycle is arrested. This problem is solved by an enzyme 
called telomerase which can produce new telomere repeats from an RNA tem-
plate. However, in normal adult cells telomerase is not expressed enough so that 
aging occurs. 
Progressed neoplastic cells can upregulate their telomerase expression or 
lengthen their telomeres by different mechanisms. A well-known method is called 
the alternative lengthening of the telomeres (ALT) where parts of other chromo-
somes are broken to fuse by recombination (breakage-fusion-cycles). 
1.5.4 Apoptosis in cancer 
Active cell death is needed during development of an organism and throughout its 
whole life to remove abnormal and damaged cells that cannot be repaired in or-
der to protect the whole body. 
On the molecular level, apoptosis is induced by typical signalling pathways: sig-
nals bind to receptors which trigger activation of intracellular effectors that lead to 
cell death. An apoptotic cell changes its morphology and typically shrinks. A con-
densation occurs and membrane-enclosed fragments (apoptotic bodies) form. 
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This is recognized by nearby cells as well as phagocytes that engulf the cell and 
prevent leakage of toxic contents that could otherwise harm the environment. 
In tumour cells this mechanism is a great barrier for growth and survival. A well-
known strategy is mutation or loss of the tumour suppressor gene p53 (see chap-
ter 1.7.3) but also a constitutive activation of the PI-3K-Akt pathway is helpful to 
prevent apoptosis (Hanahan and Weinberg, 2000). 
1.5.5 Neo-Angiogenesis 
Angiogenesis is the process where new blood vessels are built from existent ves-
sels. This normally happens during the development and wound healing. 
However, neoplastic cells need external resources to survive and therefore start 
the neo-angiogenetic program. They do so by upregulating angiogenesis promot-
ing factors including vascular endothelial growth factor (VEGF) (Ferrara et al., 
2003), hypoxia inducible factor-1 (HIF-1) (Pugh and Radcliffe, 2003) but also ma-
trix degrading proteins and proteins from the fibroblast growth factor family (FGF-
2, FGF-1) that can stimulate angiogenesis-supporting cell types. 
As is in the name, VEGF stimulates (especially vascular) endothelial cells and 
prevents apoptosis through the PI-3K-Akt pathway (discussed in chapter 1.7.2.2). 
The hypoxia inducible factor (HIF) gets stabilized when tissue parts are short on 
oxygen levels. From there it can enter the nucleus to activate target genes like 
VEGF (Ziello et al., 2007). 
1.5.6 Ability to metastasize other organs 
Metastasis is the process that enables malignant cells to invade tissues and col-
onize new organs. For that purpose, the cell undergoes an epithelial-to-
mesenchymal transition (EMT) and exploits a gene transcription program that is 
usually activated during development to conduct the progenitor-cells to their right 
places. Decreased cell-cell contacts and increased expression of proteins aiding 
in the flexibility are characteristics of this expression pattern. 
Thus, alterations affect mostly proteins involved in cell-cell and cell-ECM (extra-
cellular matrix) adhesion. Classic example is the E-cadherin expression which is 
important for sustaining the quiescent state of epithelial cell sheets through cell. 
In numerous studies, either decreased or aberrant expression of E-Cadherin is 
found in most cancer types.  
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1.5.7 New characteristics 
The already described hallmarks are still not the whole story. Additional charac-
teristics emerge as cancer research progresses. Genome instability supports 
tumour progression together with a steady inflammation that harbours many 
types of cells capable of supporting tumour tissue with all the discussed charac-
teristics (e.g. Morbus Crohn). It is also new that tumour cells change their energy 
metabolism, (even under aerobic conditions) preferably to glycolysis. 
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1.6 Colon and Rectum – a short anatomic overview 
Before taking a look at colorectal carcinogenesis, it is necessary to shortly exam-
ine the digestive system and architecture of the colon. 
When soluble and chewed food is transported through the channel called oe-
sophagus (Figure 1-9 left) to the stomach it is formed to a mash and enriched 
with gastric acid. Pancreatic juice and bile are added to this cocktail in the small 
intestine. Here, nutrients are extracted and sugar and amino acids delivered to 
the blood while lipids go through the lymphatic vessels for further processing 
(degradation). The last station is the colon where mainly the resorption of water 
takes place. 
The colon is part of the large intestine. With about 1.5 – 2 m length and 2.5 - 5 cm 
diameter it ascends on the right side, proceeds crossing to the left side, descends 
and warps to the back to form the sigmoid colon (Figure 1-9 right). This extended 
part is called rectum and is about 12 cm long. Here the indigestive remains are 
formed to a tube to excrete them through the anus.  
  
Figure 1-9 left anatomical position of colon and rectum in the body,  
right an image of the large bowel (source: patient.co.uk) 
 
  
A single-layer epithelium and an interlayer of connective tissue together make up 
the intestinal mucosa. An outer muscle layer with circular and longitudinal mus-
cles provides contraction with the latter expanding and the former constricting. 
This ensures transport of the food mash along this channel system (Brockhaus 
2011). 
Resorption is accomplished through different transport mechanisms by cells 
called enterocytes that lie along the columnar epithelium. Goblet cells secrete 
mucus to keep the intestinal lumen wet. In this way the remaining material is 
passed on to the rectum. 
Renewal of the cells takes place every 4 - 5 days from a pool of stem cells (v. d. 
Flier and Clevers 2009) that lie at the bottom of the 0.2 - 0.4 mm deep tubular 
cavities called crypts. From an asymmetric division transit-amplifying cells arise 
and proliferate every 12 hours until they turn into non-proliferating differentiated 
daughter cells. The stem cells can be regarded as progenitors of the different 
cells in the colon as they will differentiate to absorptive cells, goblet cells, hor-
mone-secreting cells and Paneth cells. 
The cell organisation in the colon is so that new cells push old ones upwards and 
the higher a cell is in the crypt, the more differentiated it is. Terminally differenti-
ated cells at the top undergo apoptosis.  
Figure 1-10 composition of the colon wall with 4 layers (written in bold) 
(source: accessmedicine.com – Junqueira’s Basic Histology 12th ed.) 
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Any malfunctioning in the stem cell renewal system can lead to a growth ad-
vantage and uncontrolled cell division which may initiate tumour development 
(Pinto and Clevers 2005). 
1.7 Colorectal Carcinogenesis 
Normal colon epithelium is renewed every 4 - 5 days by stem cells in the bottom 
of the crypts (v. d. Flier and Clevers 2009). Any mutation leading to abnormal 
growth can cause development of colonic lesions called aberrant crypt foci. Fur-
ther growth and proliferation leads to the formation of adenomatous polyps. 
When existent adenomatous polyps or intramucosal lesions progress by penetrat-
ing the submucosa, we can speak of an invasive cancer. This step will be then 
followed by a local expansion and later involve lymph nodes and the blood ves-
sels. The tumour may also infiltrate the serosa and metastasise to other organs – 
most commonly the liver and lungs. Since the rectum is lacking the serosa, me-
tastasis occurs easily.  
Fearon and Vogelstein have proposed a genetic model to answer the question, 
by which mutations CRC development is triggered (Figure 1-12). Based on the 
published data and the observations, their idea was that CRC develops stepwise 
Figure 1-11 cells in the gastrointestinal tract 
(A) cellular organisation in the small intestine (similar in the colon (without villus junction),  
(B) histologic pictures of the small intestine with arrowheads showing cell types, 
 (C) Ki-67 staining of the colon to show proliferating cells (arrows)  
(source: Pinto and Clevers, 2005) 
C 
  
through the accumulation of distinct genetic alterations - the first being a mutation 
or complete loss of the APC gene on the short arm of chromosome 5, that con-
fers growth advantage to the epithelial cells. Eventually the increased growth 
produces adenomas that can progress by acquiring mutations in the proto-
oncogene K-Ras and the gene protector p53. In addition, loss of various tumour 
suppressor genes on the long arm of chromosome 18 accounts for tumour pro-
gression. 
The role of these gene products in cancer and colorectal cancer will be described 
in the following sections. 
 
1.7.1 Wnt-pathway 
The Wnt pathway is named after the Wnt proteins that were discovered as a key 
player in the wing development in Drosophila. With distinct and often overlapping 
functions, the 19 human Wnt proteins are equipped with a fatty acid chain on their 
N-terminal site and can activate at least 3 different intracellular pathways – one of 
them being the Wnt/β-catenin pathway (often termed canonical Wnt pathway). 
Wnt binds to a seven-pass transmembrane receptor called Frizzled and the co-
receptor LDL-receptor-related protein (LRP). Recruitment of the scaffold protein 
Dvl (Dishevelled) to the cytoplasm inhibits the axin/GSK-3β/APC complex which 
cannot phosphorylate β-catenin for degradation any more. The resulting stabilisa-
tion leads to translocation of β-catenin to the nucleus and associates with 
transcription factors (TCF/LEF) that begin transcription of target genes like the 
proto-oncogene Myc, Cyclin D1 (one of the cell cycle regulators), MMP7 (matrix-
Figure 1-12 genetic model for colorectal carcinogenesis proposed by Fearon and Vogelstein  
(1990; own drawing) 
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metallo-proteinase-7) and PPARδ (a nuclear hormone receptor to regulate perox-
isome number and size). 
The canonical Wnt pathway plays an important role in developmental processes, 
especially the axis determination in the body and during limb development. 
Because it regulates expression of proteins involved in growth, the cell cycle and 
degradation of the ECM, the Wnt pathway is an important key pathway to pro-
mote cancer development (Alberts et al. 2008). 
Mutations in the APC gene lead to hyperproliferative epithelium and are one of 
the triggering events for CRC development. Germline mutations often cause the 
FAP syndrome (discussed earlier in chapter 1.3.2) which most probably lead to 
cancer formation. (Fearon and Vogelstein 1990) In about 80% of CRC cases both 
copies of the APC gene is inactivated (Alberts et al. 2008). 
1.7.2 Ras: two pathways to activate 
Ras proteins are small GTPases and play important roles in cell differentiation, 
proliferation and migration as well as adhesion. The family consists of many 
members, amongst them the proto-oncogenes N-Ras, H-Ras and K-Ras. 
Ras is a protein controlling more than one pathway and correct functioning is cru-
cial for cell homeostasis. In about 30% of colorectal cancers, mutated K-Ras is 
found and supports abnormal growth. (Calcagno et al. 2008)  
1.7.2.1 MAPK signalling pathway 
The MAPK signalling cascade is a prototypic signal transduction pathway, which 
transmits signals from outside of the cell to its interior and can be activated 
through various signals including mitogens, osmotic stress and pro-inflammatory 
cytokines.  
Upon receptor tyrosine kinase stimulation by extracellular ligands, the receptors 
dimerise and recruit adaptor protein complex GRB2-SOS. SOS is a guanine nu-
cleotide exchange factor (GEF), and induces the release of GDP from Ras, which 
is then free to bind GTP. Activated Ras recruits the protein kinase Raf to the 
membrane and enhances its activity, thereby triggering a phosphorylation cas-
cade going through Mek and resulting in Erk phosphorylation and activation. 
Activated Erk phosphorylates its targets in the nucleus, cytoplasm, cytoskeleton 
and mitochondria. This has an effect on crucial cell properties, like proliferative 
potential, survival and motility (Baccarini 2005).  
  
1.7.2.2 PI-3K-Akt pathway 
Another pathway that Ras activates is the phosphatidyl inositol-3-kinase-Akt (PI-
3K-Akt) pathway that is important for growth and survival. It does so by directly 
activating PI 3-kinase that phosphorylates membrane-bound PI(4,5)P2 to gener-
ate PI(3,4,5)P3. This serves as a docking site for two other protein kinases – the 
protein kinase B, also called Akt, and PDK1 (phosphoinositide-dependent protein 
kinase 1). A kinase that is able to phosphorylate Akt on a serine (usually mamma-
lian target of rapamycin or mTOR) is needed in order to be activated by PDK1. 
This phosphorylation leads to a conformational change of Akt so that a threonine 
is exposed and can be phosphorylated by PDK1. Active Akt dissociates and 
phosphorylates target proteins. A protein called Bad, for example, promotes 
apoptosis by inhibiting an apoptosis-inhibitory protein. Akt can release this protein 
by phosphorylation of Bad and indirectly prevent apoptosis (Alberts et al. 2008). 
1.7.3 Tumour suppressor p53 
Named after its molecular weight, p53 plays an important role in protecting the 
DNA from damage and together with p63 and p73 belongs to the p53 protein 
family. All three members can be expressed in various isoforms – two of them dif-
fering in their N-terminal domain: the TA-isoform and the partly dominant-
negative ∆N-isoform. (Levine et al. 2011) 
In a healthy cell p53 watches over the chromosomes and prevents mitosis when 
DNA is damaged. For this purpose increasing p53 concentrations arrest the cell 
in the G1 phase through upregulation of p21 that inhibits cdk2/4/6 complexes. 
Consequently, these kinases cannot phosphorylate and release Rb protein, until 
DNA repair proteins fix the problem and p53 is degraded to allow mitosis. If this is 
not possible, the cell is immediately sent to apoptosis to prevent any transfer of 
genetic alterations to daughter cells. Any malfunction of p53 enhances tumour 
formation. 
In about 80% of sporadic cancers a defect is found in p53. 40-50% of CRC have 
p53 mutations while in adenomas this occasion is rare. This demonstrates that 
p53 mutations are important at later stages of CRC development (Iacopetta, 
2003). 
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Figure 1-13 summary of signal transduction pathways 
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1.8 Fibroblast Growth Factors and their receptors 
The fibroblast growth factor family consists of 4 FGF homologous factors (FHFs) 
and 18 FGFR ligands which are essential for cell growth, morphogenesis, wound 
healing and angiogenesis. In most tumour types the expression of FGF and their 
receptors is deregulated. Based on their sequence and general function, they are 
divided into three groups:  
- FGF homologous factors FGF11-14, also called intracellular FGFs 
- canonical subfamily consisting of the subfamilies 1, 4, 7, 8 and 9 
- hormone-like FGFs (hFGFs): FGF19 (FGF15 in mice), 21 and 23 
1.8.1 FGF structure 
FGFs consist of 12 antiparallel β-strands (120-130 amino acid long, core region) 
with different N- and C-termini. In the core region a binding site for heparin sul-
phate glycosaminoglycan (HSGAG) can be found that is positively charged in 
paracrine FGFs. In the hFGFs there is a structural difference that reduces 
HSGAG binding and leads to an endocrine secretion. This work focuses on FGFs 
18 and 19. 
  
Figure 1-14 FGF structure 
(source: Beenken and Mohammadi, 2009) 
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1.8.1.1 FGF8 subfamily 
The FGF8 subfamily belongs to the canonical FGF subfamily and consists of 
FGF8, FGF17 and FGF18. All members have a signal sequence and act in a 
paracrine way preferably through binding to FGFR c isoforms (Beenken and Mo-
hammadi 2009, Zhang et al. 2006). 
The FGF8 gene can be found on the long arm of the chromosome 10 and was 
first identified as androgen-induced growth factor (AIGF) found in the conditioned 
medium of the androgen-dependent mouse mammary carcinoma. It preferably 
binds to FGFR3c but was also found associating with FGFR4. FGF8 plays an im-
portant role in forebrain patterning and in the development of brain, limbs, ears 
and eyes. Mice lacking FGF8 cannot gastrulate and defect FGF8 has been seen 
to cause reduction in limb bud size and the Kallmann syndrome (a pathologic 
condition with olfunction deficiencies and decreased gonad function) (Yun et al. 
2010, Beenken and Mohammadi 2009, Zhang et al. 2006, Powers et al. 2000). 
FGF17 is found on the short arm of chromosome 8 and has affinity for FGFR3c 
but can also bind to FGFR4, FGFR2c, FGFR1c and FGFR3b. Development of 
cerebral and cerebellar structure is impaired in FGF17 knockout mice (Powers et 
al. 2000, Yun et al. 2010, Zhang et al. 2006). 
The long arm of the chromosome 5 harbours the gene coding for the 207 amino 
acid long protein, called FGF18. FGF18 was found to be primarily expressed in 
the lungs and kidneys but also in the heart, testes, spleen, skeletal muscle and 
brain. It binds preferentially to FGFR3-IIIc but also has affinities for FGFR4 and 
weak affinity for FGFR2c (Yun et al. 2010, Hu et al.1998). 
FGF18 stimulates NIH3T3 cells, osteoblasts, chondrocytes and glial cells and 
when secreted, can influence tumour cells and cells of the connective tissue in 
the micro environment. It is an essential mitogen in the embryonic development 
of the organs as well as the cartilage and bones. Loss of FGF18 leads to severe 
skeletal diseases (Zhang et al. 2006). 
Together with FGF16, FGF20 and the controller protein sprouty4, FGF18 is a di-
rect target gene of the β-catenin/Tcf4 complex (Katoh and Katoh 2006*, 
Shimokawa et al. 2003). Constitutive activation of the Wnt-pathway (see chapter 
1.7.1) – like in most intestinal cancers – leads to an up-regulation of its expres-
sion. It was found upregulated in many adenomas and adenocarcinomas of the 
colon and was survival-supporting in vitro under starving conditions, thus exerting 
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autocrine effects. Also FGF18 treatment of colonic fibroblasts lacking serum is 
known to restore migration. FGF18 knockdown in the colorectal adenocarcinoma 
cell line via siRNA led to decreased cell proliferation and reduced colony for-
mation. (Sonvilla et al. 2008, Shimokawa et al. 2003) 
1.8.1.2 Hormone-like FGF subfamily 
Endocrine secretion of the hFGFs (FGF19, FGF21 and FGF23) arises from the 
weak binding affinity of HSGAGs that leads to an increased diffusion. Instead of 
HSGAGs, the protein klotho augments binding to FGFRs. Klotho consists of a 
single-pass transmembrane domain and an extracellular domain with two internal 
repeats called KL1 and KL2 having β-glycosidase similar sequence. It is found 
membrane bound and is secreted into the blood and cerebrospinal fluid. It can 
associate with K+, Na+ ATPases to regulate calcium homeostasis. (Beenken and 
Mohammadi 2009, UniProtKB KLOT_HUMAN, Imura et al. 2004, Kurosu and Ku-
ro-o 2009) 
The FGF19 gene can be found on the long arm of chromosome 13 and is ex-
pressed in adult gall bladder epithelium and in different fetal tissues like skin, 
retina and the small intestine. FGF19 is the human orthologue of FGF15 in the 
mouse and plays an important role in the heart development and the brain devel-
opment during the embryogenesis. Mice lacking FGF15 display increased bile 
excretion and have cardiac defects, thus not viable. It binds highly specifically to 
FGFR4 and regulates bile acid metabolism in the liver (Itoh 2010, Inagaki et al. 
2005, Ornitz and Itoh 2001, Xie et al. 1999). 
FGF21 is involved in the regulation of the energy metabolism. Its expression is 
induced under fasting conditions in adipose tissue and the liver through PPARγ 
and PPARα. Expression was also found in thymus, in pancreatic islet β-cells and 
in skeletal muscle via activation of Akt. FGF21 needs the co-factor β-klotho to 
bind FGFR4 and activate FGF signalling. Weak interaction with the c isoforms of 
FGFRs1-3 could also be detected (Beenken and Mohammadi 2009, Kurosu and 
Kuro-o 2009, Zhang et al. 2006). 
FGF23 is important for the regulation of the phosphate homeostasis and when 
mutated, leads to hypophosphataemic rickets, symptoms like growth retardation, 
bone softness and decreased phosphate levels in the blood. It is highly ex-
pressed in the bone. FGF23 acts in the kidney as a vitamin D regulator via down-
regulation of metabolizing enzymes and inhibits parathyroid hormone secretion 
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which leads to decreased phosphate uptake from the bone. FGF23 can bind to 
FGFR2c, 3c and FGFR4 but is mostly effective when bound to the FGFR1c-
Klotho complex. Like mice having mutated Klotho, FGF23-/- mice display in-
creased expression of the enzyme 1α-hydroxylase that catalyses inactive vitamin 
D to active calcitriol (1,25(OH)2D3) (Beenken and Mohammadi 2009, Kurosu and 
Kuro-o 2009) . 
 
subfamily members bind to…ᵃ plays important role in…ᵇ 
FGF1  
FGF1 
FGF2 
all FGFRs 
FGFR1c, 3c > 2c, 1b, 4∆ 
not established; loss of vascular tone and 
slight loss of cortex neurons in FGF2
-/-
 mice 
FGF4 
FGF4 
FGF5 
FGF6 
FGFR1c, 2c > 3c, 4∆ 
Limb development, cardiac valve formation 
hair growth cycle regulation 
myogenesis 
FGF7 
FGF3 
FGF7 
FGF10 
FGF22 
FGFR2b > 1b 
inner ear development 
branching morphogenesis 
“ 
presynaptic neural organizer 
FGF8 
FGF8 
FGF17 
FGF18 
FGFR3c > 4∆ > 2c > 1c >> 3b 
development of brain/eye/ear/limb 
cerebral/cerebellar development 
bone development 
FGF9 
FGF9 
FGF16 
FGF20 
FGFR3c > 2c > 1c, 3b >> 4∆ 
gonadal development, organogenesis 
cardiac development 
neurotrophic factor 
FGF19* 
FGF19 
FGF21 
FGF23 
FGFR1c, 2c, 3c, 4∆ 
 (weak activity) 
bile acid homeostasis, lipolysis, gall bladder 
fasting response, glucose homeostasis,  
lipolysis and -genesis 
phosphate and vitamine D homeostasis 
Table 1-1 information about canonical FGFs and *hFGFs, KO = knockout 
(source: ᵃ Zhang et al. 2006; ᵇ Beenken and Mohammadi, 2009) 
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1.8.2 FGFR structure 
Fibroblast growth factor receptors belong to the family of receptor tyrosine kinas-
es of the immunoglobulin (Ig) superfamily which are a class of enzyme-coupled 
receptors (Alberts et al. 2008, Grose and Dickson 2005). 
There are seven main FGFRs that are encoded from four FGFR genes. They 
consist of a cytoplasmic tyrosine kinase domain with an activation loop, a single-
pass transmembrane domain and three loop-shaped Ig ectodomains which are 
termed D1-D3. These have an acid box containing an acidic, serine-rich se-
quence between D1 and D2 that may be important for receptor autoinhibition. 
The ligand binding and specificity is regulated in the D2-D3 fragment.  
FGF receptors 1-3 can be transcribed through exon skipping to create isoforms 
that lack the D1 domain and/or the acid box. Isoforms b and c are produced by 
Figure 1-15 a structure of FGFRs, b alternative splicing creates isoforms,  
c specifity difference between the two isoforms shown in the example of FGFR2 
 (source: Turner and Grose, 2010) 
 25 
alternative splicing of the D3 domain and display distinct FGF binding affinities. 
While the b isoform is mostly found in epithelial tissue, expression of the c iso-
form happens usually in mesenchymal tissue and gets activated by a ligand 
produced in the opposite tissue. This allows signalling and thus control of epithe-
lial and mesenchymal tissue. An exception is the FGF1 that can bind to both b 
and c isoforms (Beenken and Mohammadi 2009, Grose and Dickson 2005). 
1.8.3 FGF-FGFR binding and signalling 
ECM-bound FGFs are released by a carrier protein called FGF-binding protein 
(FGFBP) and bind to HSGAGs. This complex then interacts with the FGFR and 
activates a signal transduction cascade. For this purpose, FGFRs dimerise and 
get activated via transphosphorylation on their A loop. Further phosphorylations 
serve as binding and interaction sites for different target proteins (Beenken and 
Mohammadi, 2009). 
FGFR substrate 2 (FRS2) is a protein directly associating with the intracellular 
domain of the FGFR. When phosphorylated by the receptor, it can activate two 
distinct pathways. Association with the adaptor proteins SOS and Grb2 leads to 
the activation of the MAPK pathway (described earlier in chapter 1.7.2.1). Grb2 
can also recruit Grb2 associated protein (Gab1) that starts the PI-3K-Akt pathway 
(Turner and Grose 2010). 
Phospholipase C γ (PLCγ) is another protein which, through its Src homology 2 
(SH2) domain, can bind directly to the intracellular phoshotyrosine residue near 
the carboxyl terminus. This starts an enzymatic reaction were phosphatidylinosi-
tol-4,5-biphosphate (PIP2) is hydrolysed to IP3 and diacylglycerol (DAG). These 
two products can now serve for different functions: while IP3 induces Ca
2+ from 
the smooth endoplasmic reticulum, DAG induces translocation and activation of 
protein kinase C (PKC). PKC can now phosphorylate Raf, thus activating MAPK 
signalling which supports not only proliferation but was also found to be important 
in the migration of cells for the primitive streak during chicken development. Also 
activation of STAT and ribosomal protein S6 kinase 2 is known to happen - de-
pending on cellular context. (Hardy et al. 2011, Turner and Grose 2010) 
Introduction 
26 
 
1.9 FGF-FGFR in cancer 
All receptor-ligand systems are suitable as therapeutic targets for cancer cells 
since control of these is essential for survival and progression. 
They can benefit from activating mutations of FGFR that leads to dimerization 
and constitutive activation of the receptor independent from ligand binding. Muta-
tions in the extracellular (EC) domain of FGFR2 are known causes for pathologic 
conditions like the Crouzon’s syndrome (changes in the growth pattern of the 
skull (craniosynostosis) and other facial symptoms) through autonomous covalent 
dimerization of the receptor. FGFR3 mutations in the transmembrane domain 
were found in nearly all cases of achondroplasia (hereditary short stature) (Turner 
and Grose 2010, Beenken and Mohammadi 2009). 
Figure 1-16 pathways activated through FGF ligand binding 
(source: Turner and Grose, 2010) 
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Translocations combining the N-terminus of a transcription factor with the recep-
tor kinase domain are also known to drive intracellular signalling. Constitutive 
dimerization of the kinase domain of FGFR1 is an example and leads to the 8p11 
myeloproliferative syndrome. Mutations that lead to deficient auto-inhibition of the 
FGFR2 kinase domain are another example and cause skeletal deformities but 
were also seen in endometrial cancers (Turner and Grose 2010, Beenken and 
Mohammadi 2009, Katoh 2009). 
Also gene amplifications, a known mechanism of cancer cells, can result in sus-
tained signalling through overexpression of the receptor. FGFR specificity can 
also be changed through abnormal splicing. Development of other craniosynosti-
cal syndromes may happen through gain-of-function mutations in the ectodomain 
of FGFR2c that facilitate binding of FGFR2b binding ligands. 
Elevation of FGF release from the ECM but also the stimulation of stromal cells to 
secrete more FGFs, are known mechanisms of deregulation. Amplification of 
FGF3 was found in about 15-20% of human breast cancers and correlated with 
increased invasiveness in node-negative breast carcinoma (Wesche et al. 2011). 
This process can also lead to metastasis since the ligands can act on endothelial 
cells and initiate angiogenesis (Turner and Grose 2010, Beenken and Moham-
madi 2009). 
The autocrine acting of the ligands may also inure to the benefit of cancer pro-
gression: increased production of FGF ligands can be used to self-stimulate 
cancer cells (Turner and Grose 2010). 
However, also evolutional changes like polymorphisms may contribute to the pro-
gression of pathologic conditions, especially during cancer development. Short 
nucleotide polymorphisms in the intron 2 of the FGFR2 gene were associated 
with breast cancers carrying mutations in the BRCA2 gene (Turner and Grose 
2010). 
1.9.1 FGFR4 and the G388R polymorphism in cancer 
FGFR4 plays an important role in the liver and regulates systemic cholesterol and 
bile acid metabolism as well as lipid metabolism. Disruption was found to affect 
organs like gall bladder and lead to increased cholesterol metabolism. Unlike 
FGFR1-3, it is expressed as a single isoform but displays paralogy to FGFR3c 
(Beenken and Mohammadi 2009). 
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In cancers of the prostate and breast as well as in rhabdomyosarcoma, gynaeco-
logical and gastric cancers, FGFR4 was found to be upregulated (Ye et al. 2011, 
Taylor et al. 2009, Roidl et al. 2009, Wang et al. 2008, Sahadevan et al. 2007, 
Jaakkola et al. 1993). 
As described earlier, FGF19 binding to FGFR4 is highly specific and antibodies 
blocking this interaction were found to inhibit growth of colon carcinoma xeno-
grafts (Desnoyers et al. 2008). 
Using biochemical and genetic methods, activation of FGFR4 was found to inhibit 
NFκB signalling and negatively affect proapoptotic signalling (Drafahl et al. 2010).  
Recently, an FGFR4 polymorphism is gaining importance in the cancer research. 
A single point mutation in the transmembrane domain at position 388 causes re-
placement of glycine to an arginine. About 45% of all white population examined 
were hetero- or homozygous for the R388 allele (Wang et al. 2008). 
Association between this polymorphism and cancer prognosis was investigated 
by Frullanti et al. in a meta-analysis including cancers affecting brain, breast, col-
orectal, head and neck, larynx, lung, melanoma, prostate and sarcomas. They 
showed that FGFR4-R388 led to an increased risk of poor survival than people 
homozygous for FGFR4-G388. FGFR4-R388 homozygosity was also significantly 
associated with nodal involvement (Frullanti et al. 2011). 
Figure 1-17 FGFR4 and location of the G388R polymorphism  
(source: C. Heinzle) 
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Table 1-2 information about different pathologies involving FGFRs  
(source: Turner and Grose 2010) 
receptor amplification mutation translocation 
FGFR1  
Breast, ovarian, bladder can-
cers and rhabdomyosarcoma 
melanoma 
Myeloproliferative syn-
drome 
chronic myeloid leuke-
mia 
FGFR2 Gastric and breast cancers 
Endometrial and gastric cancer 
Germline SNP in the 2
nd
 intron: 
increased breast cancer inci-
dence 
 
FGFR3 
Bladder, salivary adenoid 
cystic cancers 
 
bladder cancer (mostly non-
muscle invasive), cervical can-
cer, myeloma, spermatocytic 
seminoma 
Myeloma 
Peripheral T cell lym-
phoma 
FGFR4 
 G388R SNP on the TM domain: 
better progression of cancers 
of the breast, prostate, neck 
and lung  
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2 Aim of the thesis 
The exact role of the FGFR4 G388R polymorphism in CRC is not yet sufficiently 
understood. 
The aim of the thesis was to investigate this in CRC cell lines. Using FGFR4 
overexpressing colorectal carcinoma cell lines, the main focus of attention was to 
examine effects on survival, growth and different malignant characteristics like 
migration, invasion and attachment as well as the EMT state. Whether FGFR4 
overexpression alters intracellular behaviour and if so, through which signalling 
pathways this happens, was another goal to be achieved. 
 
  
 33 
3 Materials and Methods 
3.1 Cell lines 
Cell lines that were obtained from the American Type Culture Collection include 
ATCC® numbers (Table 3-1). 
3.1.1 HT29 
HT29 is a colorectal adenocarcinoma cell line with an epithelial morphology and 
adherent growth. The cells were first isolated in 1964 from a 44 year old Cauca-
sian woman. They express c-myc, K-ras, H-ras, N-ras, fos and overexpress 
mutated p53.  
Cells were cultured in 10%MEM and grown to 80% confluence prior to splitting 
(1:5 - 1:10). Renewal of the medium occurred every two days and 0.45 mg/ml G-
418 was added to transfected cells. 
3.1.2 HCT116 
The growth of HCT116 cells is adherent and their morphology epithelial. They are 
colorectal carcinoma cells and were derived from an adult male. Among TGFβ1 
and TGFβ2 they also express mutated ras.  
Passaging was done 1:10 - 1:20 after full confluence in 10%MEM while renewing 
medium once in a week. Transfected cells received 0.5 mg/ml G-418 for selection 
purposes. 
  
HT29 
HTB-38™ 
HCT116 
CCL-247™ 
SW480 
CCL-228™ 
Caco-2 
HTB-37™ 
Table 3-1 appearance of cell lines obtained from ATCC 
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3.1.3 SW480 
Dividing every 24 hours SW480 cells are primary colorectal adenocarcinoma cells 
at an early invasive tumour stage and originate from a 50 year old Caucasian 
male. With a positive expression profile of c-myc, mutated Ki-ras, fos and mutat-
ed p53 they grow adherent and display an epithelial morphology.  
New medium was added once a week and passaged 1:10 - 1:20 at a confluency 
of 90 - 100%. Cells containing vector got 0.3 mg/ml G-418 additionally. 
3.1.4 Caco-2 
Obtained from a 72 year old Caucasian male, Caco-2 cells display epithelial mor-
phology and grow adherent with a doubling time of about 62 hours. They are 
derived from colorectal adenocarcinoma and, upon confluence, differentiate into 
enterocytes.  
This cell type is cultured in 20%MEM and grown to a confluency of 90-100%. 
Medium was exchanged twice a week. 
 
cell line origin description 
LT97-1 ICR MUW colon microadenoma cell line 
LT97-2 ICR MUW later passage of LT97-1 
T84 
72 year old male 
(ATCC) 
CRC derived lung metastasis 
SW620 
51 year old male 
(ATCC) 
colorectal adenocarcinoma  
at Dukes’ type C (lymphatic invasion) 
AKH4 
Caucasian male 
(ICR MUW) 
CRC derived liver metastasis 
AKH14 
Caucasian male 
(ICR MUW) 
Different passage of AKH4 cells, 
less differentiated 
Table 3-2 information about other used cell lines 
 
3.2 Cell culture 
Cells were cultured either in 10 cm or in 6 cm petri dishes depending on their us-
age under default conditions: 37°C 5% CO2. 10% MEM refers to Eagle’s minimal 
essential medium (Sigma-Aldrich) with 10% of fetal calf serum (PAA). After wash-
ing with 10mM PBS/EDTA (Merck), cells were detached with trypsin/PBS (PAA). 
Counting of cells occurred with a counting chamber using a microscope. 
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3.3 Transfection 
3.3.1 Stable FGFR4 expressing cell lines 
To create the cell lines overexpressing FGFR4arg or FGFR4gly allele, we trans-
fected HT29, HCT116 and SW480 cells using lipofection.  
This method uses liposomes to introduce vectors of interest into a cell. The phos-
pholipid bilayer of these liposomes allows a cell fusion, thereby releasing the 
DNA-cargo into the cytoplasm. 
We obtained TransFectin™ Lipid Reagent (Bio-Rad, Philadelphia, PA, US) and 
seeded 3x105 cells per well of a 6-well plate. After 24 – 48h we renewed the me-
dium and prepared transfection reagent. 10µl TransFectin was added to a total 
volume of 250µl SFM. 2µg plasmid was prepared in an extra tube also in 250µl 
SFM. The plasmids were kindly provided by Axel Ullrich (Max-Planck-Institut, 
Germany) and contained an FGFR4gly or 
FGFR4arg gene at the multiple cloning site 
of a A3 vector (Figure 3-1). An ampicillin 
resistance marker for selection in E. coli 
and a neomycin resistance for selection of 
stably expressing higher cell clones were 
also on the plasmid. The DNA and Trans-
fectin solutions were mixed and after 20’ of 
incubation, 1.5ml was added to each well of 
the plate. The medium was exchanged 6h 
later to minimize toxicity on cells. 
The cells were transferred to 10cm petri 
dishes after 24h, and 48h later the aminoglycoside antibiotic Geneticin (G-418) 
was added to select cells stably expressing the vector. For each cell line different 
concentrations were used: 
- 1.0 mg/ml for HCT116 
- 0.6 mg/ml for SW480 
- 0.9 mg/ml for HT29 cells 
 
Figure 3-1 map of the used vector 
Materials and Methods 
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3.3.2 FGF18 knockdown 
24 hours after setting 5x105 cells to 6cm PDs the cells were transfected with 
FGF18 siRNA oligos. For this purpose, 9µl silentFect reagent was diluted with se-
rumfree medium containing 0.1% BSA to a volume of 750µl and added to equal 
volume of 40nM siRNA (scrambled siRNA served as control). Cell medium was 
removed and 1.5ml fresh medium was added. After 20 minutes incubation of the 
transfection solution, 1.5ml was added to each plate for a total volume of 3ml. 
24 hours later medium was changed to SFM 0.1% BSA to starve cells and protein 
was isolated for western blot analysis. 
3.4 Viability 
3.4.1 Neutralred assay 
1 – 2 x103 cells were seeded in 24-well plates for a total volume of 500µl.  
For stimulation experiments the cells were starved in SFM for another 24hours 
and then stimulated with 10ng/ml either FGF18 or FGF19 (human, recombinant, 
P10052, P9122 from Biovision) in SFM 0.1%BSA. Medium without factor served 
as a negative control. 
At the time point given in the figures (24 hours for standard experiments, daily for 
growth curves) medium was changed to freshly made neutralred (Merck) solution 
(in 0.05 mg/ml serum free medium containing 0.1% BSA) and incubated at 37°C 
for 2 hours. The cells were then washed with PBS and cell bound neutral red was 
extracted by neutralred-fix solution.  
 
Neutralred-fix solution 
1%  acetic acid 
70%  ethanol 
 bidist. water 
Table 3-3 neutralred-fix solution 
 
This assay is based on the reaction in the lysosome of the cells that results in a 
colour change to pink. The colour intensity correlates with the concentration of liv-
ing cells and is measured at the wavelength 620nm (and 562nm as reference). 
 
 37 
3.5 Migration in vitro 
Analysis of migration behaviour of cells was done by using the following assays 
described below. 
3.5.1 Migration Assay – Transwell assay 
This assay works with microporous filters of 8µm pore size obtained from BD. 
Triplicates for each approach in a 24-well plate were used and each well was 
filled with 800µl of the appropriate medium. 104 cells in 200µl medium were 
seeded into the inserts. Depending on the cell line used, the cells in the well were 
fixed with methanol after 3 – 4 days, stained with crystal violet and counted by 
visual means. 
3.5.2 Scratch Assay 
For this assay we seeded 1 - 1.5 x106 cells into each well of a 6-well plate and a 
scratch was made using sterile white tips after adhesion phase (24 - 48h). Wash-
ing at least once with P/E removed detached swimming cell clusters and dead 
cells. Medium was changed to either 10% MEM for positive control, starving me-
dium for negative control or starving medium with FGF18 or FGF19 in appropriate 
concentrations. Photos were taken at 4x magnification during the following day up 
to 24h. For each approach three wells were used and scratch width was meas-
ured from four different positions of each well using Photoshop. The percentage 
of original scratch width was calculated (    
            
             
). 
3.5.3 Invasion assay 
Cell culture inserts (for 24-well plates, obtained from BD Biosciences) were coat-
ed with 28µl collagen (from Sigma, 0.01% diluted 1:12.25 in 1xPBS) and 
incubated in the appropriate plate at 37°C o/n. The next day 4x104 cells were 
seeded in 200µl 10% MEM into the inserts with 800µl 20% MEM in the wells. Fil-
ters were removed after 3-4 days. Cells were fixed with methanol after several 
days of growth. Crystal violet was used for staining. 
Testing approaches were done with different coating reagents (Table 3-4). Mat-
rigel™ was obtained from BD Biosciences. 
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Table 3-4 dilutions of used coating reagents 
12/24µl Matrigel 12/56µl Collagen 
2 
1 
No dilution 
24.5 
12.25 
6.125 
 
3.6 Attachment assays 
3.6.1 Clonogenicity assay 
100 cells were plated into each well of a 6-well plate, using triplicates for each 
experimental group. This simulates the metastasis where small numbers of tu-
mour cells have to settle down to a new environment and grow autonomously 
without any contact to other cells. Therefore this method is also known as “colony 
formation assay”. 
To select cells attached within 24h, we exchanged medium to 10%MEM after 24h 
to stimulate cell growth. After colony formation (usually five days later), we fixed 
the cells with methanol and stained with crystal violet. The cell colonies were 
counted by visual means. 
3.6.2 Adhesion assay 
100 cells were applied for each well of a 96-well plate, using 6 wells for every ap-
proach. 24 hours later the wells were washed and fixed with methanol. After 
staining with crystal violet the number of cells was determined using microscopy 
at 10-fold magnification. 
3.7 Gene expression methods 
3.7.1 Standard Realtime-PCR 
3.7.1.1  RNA isolation 
Cells were seeded in 10cm plates at a concentration of 2x106 and RNA isolated 
using Trizol (peqGold Trifast, peqLab). After 5 minute incubation in 1ml Trizol the 
cells were scraped and transferred into eppendorf tubes. The tubes were vor-
texed with chloroform and left for phase separation for ten minutes at room 
temperature. They were centrifuged at 15,000 rpm for 15 minutes at 4°C and up-
per phase was transferred to new tubes. RNA was precipitated with isopropanol 
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for ten minutes and centrifuged at 12,200 rpm at 4°C. The pellets were washed 
with EtOH (70% in bidest. water treated with DEPC for RNase free working) and 
centrifuged again for 15 minutes. After resuspension in 30µl water (DEPC treated) 
RNA was denaturated at 65 - 70°C for 10 minutes. 
3.7.1.2  Complementary DNA synthesis 
RNA concentration was calculated using nanoDrop spectrophotometer (peqlab) 
(µg/µl= 
                               
    
) and 1 - 5µg of RNA in 10µl was used for cDNA 
synthesis. 100µM Random Hexa-Primer (Fermentas) were added and incubated 
for 5 minutes at 70°C. Mastermix was prepared containing buffer, dNTP Mix and 
RNase Inhibitor (both Fermentas) and then added and incubated at 25°C for 5 
minutes. Finally reverse transcriptase (Revert Aid™ M-MuLV, Fermentas) was 
added to start complementary DNA synthesis. The following program was then 
applied: 
- 10 minutes at 25°C 
- 60 minutes at 42°C 
- 10 minutes at 70°C 
80µl DEPC treated bidistilled water was added and stored at -20°C. 
3.7.1.3  RT-PCR 
Polymerase chain reaction is a method to amplify DNA sequences. The main 
steps are denaturation of the double stranded DNA, annealing of the primers and 
elongation by using dNTPs. Repeating these steps, results in an exponential in-
crease in the amount of the DNA sequence to be amplified. 
Realtime-PCR uses labelled primers for realtime measurement of DNA amount. 
The outcome is the Ct value which is the lowest cycle number in the linear in-
crease of the signal-cycles curve.  
For the actual PCR, 96-well plates (MicroAmp® Fast Optical 96-Well Reaction 
Plate) were used and mixed solutions (Table 3-5) were pipetted to a total volume 
of 10µl for each well. 
 
 
4.5 µl cDNA-Mix 5.5 µl TaqMan®-Mix 
1.0 µl cDNA 
3.5 µl NCF water 
0.5 µl TaqMan® (ABI) 
5.0 µl TaqMan® Supermix 
Table 3-5 used amounts for RT-PCR 
Materials and Methods 
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Taqman probes contain the dye 6-carboxyfluorescein (FAM) and the appropriate 
primers. Every analysis was made in triplicates to exclude mistakes made during 
pipetting. The amplification and quantification was done on an ABI Prism 7000 in-
strument which reads out the intensity of the signal. Non-template controls served 
as negative controls without any cDNA. 
 
Table 3-6 used cycling conditions for realtime-PCR and used probes for analyses 
step condition  TaqMan probes 
initiation 
denaturation 
annealing/elongation 
10’ at 95°C 
15’’ at 95°C 
1’ at 60°C 
 FGFR4 (Hs00242558_m1) 
FGF18 (Hs00818572_m1) 
FGF19 (Hs00391591_m1) 
40 cycles  
 
3.7.2 Allelic Discrimination 
In order to make sure our generated cell lines were overexpressing the correct 
FGFR4 alleles a different type of RT-PCR protocol was used with appropriate 
primers for the two alleles. This analysis was done on an ABI Prism 7500 device. 
For this purpose a calibration curve made by Christine Heinzle was used to read 
out the FGFR4arg/FGFR4gly ratio in the cells (Table 3-8, see thesis C. Heinzle 
2011).  
 
 
Reagent [stock] µM [final] µl / reaction  step condition 
Genotyping MM 2x 1x 5.00  initiation 2’ at 50°C 
Forward primer 100 900 0.09  denaturation 10‘‘ at 95°C 
Reverse primer 100 900 0.09  annealing 15‘‘ at 95°C 
Probe Arg388 (FAM) 100 100 0.01  elongation 1‘ at 60 °C 
Probe Gly388 (VIC) 100 100 0.01  40 cycles 
NCF water   2.80    
cDNA   2.00    
  Total 10.00    
Table 3-7 RT-PCR protocol and cycling conditions for allelic discrimination 
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Table 3-8 calibration curve for calculation of Arg/Gly ratio in a sample 
(kindly provided by Christine Heinzle) 
 
 
 
 
 
 
 
 
3.7.3 Immunological detection of proteins 
3.7.3.1  Protein isolation 
About 5x105 cells were used for 6cm or 2x106 for 10cm petri dishes and medium 
was changed for starving medium. Then cells were stimulated for 5 and 15 
minutes with 10ng/ml either FGF18 or FGF19. For analysis of phosphorylated 
proteins, we added the phosphatase inhibitors 1M sodium fluoride (NaF, 1µl/ml) 
and 1M sodium orthovanadate (Na3VO4, 10µl/ml) immediately after the incubation 
period. These reagents inhibit Ser/Thr and acidic phosphatases as well as Tyr 
and alkaline phosphatases. The plates were washed with ice cold 1xTBS contain-
ing NaF and Na3VO4 (pH 7.6) and proteins were isolated by scraping under cold 
conditions. After a short centrifugation step the pellet was resuspended and incu-
bated in 40µl lysis buffer at 4°C for 30 minutes. To aid in cell lysing, the protein 
lysates were vortexed at least three times in between. Ultrasonic treatment was 
done and centrifuged at 15,000rpm for five minutes to remove insoluble fragment.  
 
lysis buffer 
1M  Hepes 
1M  NaCl 
0.5M  EDTA 
1M NaF 
1M NaVO4 
1M MgCl2 
 complete 
 Igepal 
 Bidist. water 
Table 3-9 lysis buffer contents 
2.687 Arg  
0.888 08:01 
0.440 03:01 
0.274 02:01 
0.149 01:01 
-0.323 01:02 
-0.501 01:03 
-0.927 01:08 
-2.269 Gly 
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42 
 
The supernatants containing the proteins were transferred to new tubes and pro-
tein concentration was measured using equal amounts of Bio-Rad Coomassie’s 
Protein Assay Dye Reagent. Known BSA concentrations were used for calibration 
curve and absorption was measured at 590nm.  
 
Table 3-10 pipetted amounts for determination of protein concentration 
[µg/µl] BSA 0 1 2 3 4 5 6 
Aqua bidest [µl] 9 8 7 6 5 4 3 
Lysis buffer [µl] 1 1 1 1 1 1 1 
BSA [µl] 0 1 2 3 4 5 6 
 Total 10µl 
3.7.3.2  SDS-PAGel electrophoresis 
Protein concentrations were calculated and the right amount for 50µg protein was 
prepared with half of 4x sample buffer. 
 
Table 3-11 sample buffer and TBS contents 
4x sample buffer 1x TBS (1L) 
  4%  SDS 
20%  Glycerol 
10%  2-mercaptoethanol 
0.125M Tris/HCl pH 6.8 
 Bromphenol blue 
 Bidist. water 
0.02 M Tris 
1.40 M NaCl 
 Bidist.water 
 HCl to pH 7.6 
 
 
For protein separation 12% separating gel and 4% stacking gel was made and 
incubated at RT, each for one hour to polymerize. Protein lysates containing 
50µg protein were denaturated for five minutes at 80°C and adjacently loaded to 
the gel. We used 5µl PageRuler™ Prestaind Protein Ladder (Fermentas) as a 
marker. 
 
Table 3-12 contents of used buffer 
10x Electrophoresis buffer 10x Blotting buffer 
14.4% Glycin 
3.0%  Tris 
1.0%  SDS 
14.4% Glycin 
3.0%  Tris 
0.2%  SDS 
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The gel was run in 1x electrophoresis buffer at 60V for 15 minutes to concentrate 
proteins and then the voltage was increased to 125V for another 1¾ hours to 
separate proteins according to their molecular weight. Used device was pur-
chased from Bio-Rad. 
3.7.3.3  Blotting on membrane 
For each gel six pieces of filter paper and a piece of Polyvinylidene Fluoride 
(PVDF) membrane was cut to the appropriate size and soaked in blotting buffer 
(1:10 diluted from 10x concentrated buffer and 20% methanol added). The mem-
brane was activated in methanol prior to sandwich assembly and then blotted o/n 
at constant 25V using PerfectBlue™ Tank Electro Blotter (peqlab).  
 
Table 3-13 assembly of the blotting sandwich 
black/(-) pole 
thick pad 
2x filter paper 
gel 
membrane 
2x filter paper 
thick pad 
red/(+) pole 
 
The membrane side containing proteins was labelled at one edge and flushed 
with bidistilled water. To test the blotting success we incubated the membrane in 
a solution of Ponceau Red stain (Sigma). 
The membrane was then washed in TBST 0.1% and blocked with 5% BSA to ex-
clude unspecific binding of antibody molecules. After a repeated washing step the 
first antibody (Table 3-14) was incubated o/n. 
The blots were then washed again and incubated with an HRP conjugated sec-
ondary antibody (goat anti-rabbit IgG-h+I in 3% BSA TBST0.1%, BETHYL 
laboratories and goat anti-mouse, Thermo Scientific) for an hour. Before detec-
tion, the blots were washed again and reagents prepared. The detection was 
done by incubating the blots for at least 5 minutes with a mix containing equal 
amounts of luminol solution and peroxide solution (Amersham ECL™ Prime 
Western blotting detection reagent, GE Healthcare). The blots were incubated in 
stripping buffer for 30-45’ to remove unwanted antibodies and blocked anew. 
Methanol was applied before storage at 4°C.  
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Table 3-14 information about used antibodies 
origin antibody company … dilution … 
rabbit 
pErk1/2 
(Thr202/Tyr204) 
Cell signalling (US) 1:2000 in 3% BSA TBST 0.05% 
rabbit total Erk1/2 upstate (US) 1:5000 in 5% BSA TBST 0.05% 
rabbit pS6 (Ser235) Signalway Antibody (US) 1:1000 in 3% BSA TBST 0.1% 
rabbit total S6 Cell signalling (US) 1:2000 in 3% BSA TBST 0.1% 
rabbit pGSK3β Cell signalling (US) 1: 1000 in 3% BSA TBST 0.05% 
rabbit total GSK3β Cell signalling (US) 1: 1000 in 3% BSA TBST 0.05% 
rabbit 
pPLC-γ1 
(Tyr783) 
Cell signalling (US) 1:1000 in 3% BSA TBST 0.05% 
rabbit total PLC-γ1 Cell signalling (US) 1:1000 in 3% BSA TBST 0.05% 
rabbit pSrc (Tyr418) ABM (CA) 1:1000 in 3% BSA TBST 0.1% 
rabbit total Src ABM (CA) 1:1000 in 3% BSA TBST 0.1% 
mouse β-actin Sigma-Aldrich (US) 1:500 in 1% milk PBST 0.05% 
 
 
Stripping buffer 
0.10 M 
0.05 M 
2 % 
β-mercaptoethanol 
Tris pH 6.8 
SDS 
Table 3-15 stripping buffer contents 
 
3.7.4 FACS 
106 Cells were trypsinized and pelleted at 1,100 rpm for 5 minutes. After washing 
with PBS, the pellet was resuspended in 200µl and divided equally to two distinct 
tubes to distinguish positively and negatively labelled probes. 30µl FCS was add-
ed for blocking purposes and incubated for 10 minutes on ice. 
In the meantime PE labelled antibody (anti-human CD334, Biolegend) was pre-
pared in the right concentration to a total volume of 13µl. For the control tube an 
anti-mouse control antibody was used. 
The tubes were wrapped in aluminium foil to assure a dark environment and in-
cubated for 45 minutes in a box. After washing with PBS the supernatant was 
discarded and pellets resuspended in 500µl PBS. The solution was transferred to 
new FACS tubes and submitted to Irene Herbacek for FACS analysis. 
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3.7.5 Immunological staining 
For this method 2.2 x 104 cells were prepared in 100µl. Autoclaved flexible cell 
culture chambers (contain 12 wells, FlexiPERM®) were set onto sterile glass 
slides and coated with 100µl collagen. 10 minutes later the collagen solution was 
removed and cell suspension was pipetted into the wells. Depending on the cell 
line this construct was incubated for 24h or 48h at 37°C to ensure cell adhesion 
and standard protocol was implemented. Pictures were taken at 60x magnifica-
tion. 
 
step reagent with concentration time span and cond. 
Fixation 
4% formaldehyde 30‘at -20°C 
3:1 methanol/aceton 2‘-5‘ at -20°C 
Washing cold 1x PBS 5‘ at RT 
Clamping into slide rack (Shandon “Sequenza“) 
Inactivation NH4Cl solution 5‘ at RT 
Washing cold 1x PBS 5‘ at RT 
Permeabilisation 0.5% Triton X in 1x PBS 5‘ at RT 
Washing cold 1x PBS 5‘ at RT 
Blocking 0.2% fish gelatine in 1x PBS 30‘ at RT 
1st antibody 1:100 in fish gelatine sol. 60‘ at RT 
Washing 3x with cold 1x PBS 3x5‘ at RT 
Continued in the dark 
2nd antibody 
1:1,000 in fish gelatine sol. 
with 1:100,000 To-Pro®-3 Iodide 
(#A-11001, invitrogen) 
45‘ at RT 
Washing 
3x with cold 1x PBS 
bidistilled water 
3x5‘ 
5‘ at RT 
Covering cold Mowiol® (polyvinyl alcohol 4-88 Fluka) 
Table 3-16 detailed protocol of immunostaining 
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3.7.6 Enzyme-linked Immunosorbent Assay 
An ELISA kit for pFRS2 was obtained from R&D Systems (KCB5126)  and en-
closed protocol applied. 
104 cells were seeded in each well of a 96-well plate and incubated two days at 
37°C. Every approach was set four times including one for the negative control. 4% 
formaldehyde was used to fix the cells followed by three times washing. Quench-
ing buffer (0.6% H2O2 in washing buffer) was added and incubated at RT for 20’.  
After washing, the cells were blocked to prevent unspecific binding of the anti-
body and washed again. The primary antibody-mix was prepared, 100µl added to 
each well and incubated o/n at 4°C. The same amount of blocking buffer was 
used for negative controls.  
The next day cells were washed and treated with the secondary antibody-mix for 
2h at RT. After washing with buffer and 1xPBS, the 1st substrate was added to 
each well followed by the 2nd substrate addition (without aspiration) with a 40’ in-
cubation time for each at RT. The plate was read at an excitation wavelength of 
540nm and emission wavelength of 600nm for pFRS2 (Y436) using a fluorimeter. 
For FRS2 the plate was read again at 360/450nm.  
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4 Results 
4.1 Expression results 
4.1.1 FGFR4 ligand screening in various colon cancer cell lines 
Expression level of the FGFR4 ligands FGF18 and FGF19 was checked in differ-
ent colon cancer cell lines. Figure 4-1 shows results normalized on SW480 levels. 
In the adenocarcinoma cell line HT29 there is hardly any FGF18 while FGF19 is 
expressed at a similar level as in SW480’s. Caco-2 cells do not seem to express 
either of the ligands. In SW620, a colorectal adenocarcinoma at lympho-invasive 
stage and in the CRC cell line HCT116, high FGF19 levels could be detected 
while FGF18 was rather low in the latter. The microadenoma cell lines LT97 and 
in cell lines derived from metastastic tissues (T84, AKH4 and AKH14) low FGF19 
and low FGF18 expression was determined. Interestingly LT97-2 cells which 
were derived from later passages of LT97-1 and AKH14 that are less differentiat-
ed but derived from the same tissue of AKH4, had moderate levels of FGF19.  
4.1.2 FGFR4 ligand screening in transfected cell lines 
Expression of the FGFR4 ligands FGF18 and FGF19 was also investigated in Arg, 
Gly and the control pcDNA transfectants. As Figure 4-2 shows, both over-
expressing cell lines – Arg and Gly – showed minimal FGF19 expression. In Arg-
transfectants, FGF18 is expressed less than in the control while FGFR4gly over-
expression led to high FGF18 mRNA.  
Figure 4-1 FGF18 and FGF19 expression results in various colon cancer cell lines, 
in x-fold expression levels (SW480 taken as 1) 
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4.1.3 FGFR4 expression in transfected cells 
In Figure 4-4, FACS analysis results are presented that demonstrate high FGFR4 
expression levels in both HT29 Gly and HT29 Arg cells compared to the control.  
SW480 cells transfected with the FGFR4arg vector have more FGFR4 on their cell 
surface than FGFR4gly transfectants. When compared to the control cell line they 
both overexpress FGFR4. FACS analysis confirmed the RT-PCR results of 
SW480 cells (Figure 4-4, C. Heinzle thesis 2011). 
 
  
Figure 4-2 FGF18 and FGF19 mRNA expression in transfected SW480 cells 
Figure 4-3 FGFR4 expression results in transfected HT29 cells 
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4.1.4 FGFR4 allelic determination in transfected cells 
The expression of the specific alleles was also checked by RT-PCR.  
Table 4-1 shows that in HT29 cells transfected with the FGFR4arg vector the ex-
pression is HT29arg only while HT29gly cells express threefold more FGFR4gly than 
FGFR4arg. The control cell line (depicted as pcDNA in the table) has three times 
more Arg expression than Gly (see Materials and Methods). 
 
HT29- primer mean Arg - Gly R:G ratio  2,687 Arg only 
A
rg
:G
ly
 r
a
ti
o
 
Arg fgfr4_a 29,54 29,54 Arg only  0,888 08:01 
  fgfr4_g 0,00     0,44 03:01 
Gly fgfr4_a 35,34 1,26 1: 4  0,274 02:01 
  fgfr4_g 34,09     0,149 01:01 
pcDNA fgfr4_a 34,17 -3,84 4: 1  -0,323 01:02 
  fgfr4_g 38,01     -0,501 01:03 
 
-0,927 01:08 
-2,269 Gly only 
 
Table 4-1 left calculation of FGFR4
arg
:FGFR4
gly
 ratio in transfected HT29 cell lines, 
note the colour coding described in the right panel 
 
 
 
4.1.5 Influence of FGFR4 on the expression of EMT markers 
Expression of EMT markers Vimentin and Fibronectin were checked using fluo-
rescein-labelled antibodies. Vimentin expression results are depicted in Figure 
4-5. In HT29 FGFR4 overexpressing cells there was more fluorescent stain than 
in the control cell line pcDNA and untransfected HT29 cells. In SW480 cells the 
pictures show low expression in the Arg cells, more concentrated on the plasma 
Figure 4-4 SW480 cells (lower panel) using different methods 
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membrane. SW480gly cells were approximately the same level as the control cells 
and the untransfected SW480’s. 
In Figure 4-6 transfected HT29 and SW480 cells are compared with untransfect-
ed cells. An elevated fibronectin expression could be seen in FGFR4 
overexpressing HT29 cells, concentrated on the plasma membrane. In SW480 
transfectants the expression decreases in the following order: Gly – untransfected 
– pcDNA – Arg.  
Figure 4-6 Fibronectin expression of transfected and untransfected  
HT29 (upper panel) and SW480 (lower panel) cells 
Figure 4-5 Vimentin expression of transfected and untransfected  
HT29 (upper panel) and SW480 (lower panel) cells 
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4.2 Viability 
Growth of the cell lines HT29, SW480 and HCT116 was recorded over a period of 
six days. Values depicted in Figure 4-7 values were normalized to viability on the 
first day and percentages were plotted. The plots of HT29 and SW480 cells show 
high statistical variations, thus precluding significant differences. Transfected 
HCT116 cell lines grew similarly and did not show any big differences. 
 
Growth of the transfected cells was investigated over five days with stimulation of 
the FGFR4 ligands FGF18 and FGF19 (10ng/ml). As was described in chapters 
4.1.1 and 4.1.2, HT29 cells expressed little FGF18 while the transfected SW480 
cells displayed moderate FGF18 but hardly any FGF19 production. Because of 
this, FGF18 was selected for stimulation of HT29, and FGF19 for SW480 cells. 
 
In general, SW480 cells were growing faster than HT29 cells (Figure 4-7 and Fig-
ure 4-8). When the transfected cell lines were compared with each other, we 
could see no differences in the HT29 derived cell lines (Figure 4-8 upper panel).  
In SW480s (Figure 4-8 lower panel), FGFR4arg transfected cells were growing 
faster than the cells overexpressing FGFR4gly or the empty vector pcDNA3.1.  
When we analysed FGFR4 ligand effects we could see some differences in the 
Gly cell line (Figure 4-8 upper panel): there were slightly more untreated cells on 
day 4 than cells which were factor treated. However, the standard deviations 
were too high, precluding any significance. 
 
Figure 4-7 growth curves of different transfected cell lines as labelled in the titles of the graphs 
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Figure 4-8 transfected HT29 (upper panel) and SW480 (lower panel) cell growth recorded over  
five days, 1st day taken as baseline; note the different y-axis in the plots; error bars represent ±SD 
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4.3 Adhesion and colony formation in FGFR4 transfectants 
To determine effects of the FGFR4 G388R polymorphism on the attachment and 
colony formation ability of cells in the absence of any cell-cell contacts, clonogen-
icity experiments were performed in the presence of FGFR4 ligands FGF18 and 
FGF19. In Figure 4-9 the results of FGF18 stimulation are shown. Different 
FGF18 concentrations do not seem to affect the clonogenic ability. However, as 
expected from our previous studies (see C. Heinzle thesis 2011), an effect of the 
FGFR4 alleles could be detected (Figure 4-9 and Figure 4-10: +control): cells 
transfected with FGFR4gly achieved better attachment and colony formation than 
the FGFR4arg overexpressing cells. 
 
  
Arg 
Gly 
pcDNA 
growth medium untreated 1ng/ml 5ng/ml 10ng/ml FGF18 
Figure 4-9 clonogenicity assay to test cell adhesion and colony formation at low cell density: 
 transfected SW480 cells without and with FGF18 treatment; bars represent ±SD 
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The same experimental approach was used for different concentrations of FGF19 
(Figure 4-10) and the same enhancing effect of FGFR4gly on attachment and col-
ony formation was observed. Apart from this, in FGFR4 overexpressing cells, 
especially the Arg allele, FGF19 led to a decrease of the cell colony number. 
 
  
Arg 
Gly 
pcDNA 
growth medium untreated 1ng/ml 5ng/ml 10ng/ml FGF19 
Figure 4-10 FGFR4
arg
 or FGFR4
gly
 overexpressing SW480 
tested on their clonogenic ability with or without FGF19 stimulation; bars represent ±SD 
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4.3.1 Adhesion assay 
To investigate the adhesion capability of cells independent of their growth poten-
tial, we used standard adhesion assay on our transfected cells with stimulation of 
FGF19. Results are shown in Figure 4-11. The positive controls grown in conven-
tional growth medium attached as expected and confirmed the results of the 
clonogenicity experiments (chapter 4.3): SW480gly cells showed better adhesion 
than cells overexpressing FGFR4arg. Also in the negative control, SW480gly cells 
attached slightly better than SW480arg cells. 
When different concentrations of FGF19 were added, both transfectants attached 
better and a characteristic pattern could be seen: while in FGFR4arg overexpress-
ing cells the adhesion remained constant, in SW480gly we saw that 1ng/ml was 
the optimal concentration for attachment and increasing concentrations of FGF19 
led to reduced adherence.  
 
  
Figure 4-11 tested adhesion experiment on transfected SW480 cells; * p < 0.5; 
Unconnected asterisks above bars represent significance between Arg and Glydata;  
asterisks on columns represent significance to control 
* 
* 
* 
* * 
* 
* *   * * 
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4.4 Migration to close the scratch 
4.4.1 Development of a scratch assay protocol 
In order to develop a protocol for scratch assay experiments, scratches were 
made on cell monolayers at different cell densities and photos taken after several 
time points to find the optimal time span for migration.  
To stimulate the cells for migration a nearly 100% confluency was used. For this 
purpose two experimental groups were used with 700,000 and a million cells per 
6-well. The scratch was made with yellow tips which led to swimming cell clusters. 
For that reason, white tips were used to make the scratches and photos were 
taken to record original width. 24 hours later the new width was determined using 
microscope at 4x magnification. 
As Figure 4-12 shows scratch closure was the same in both densities.  
 
Further, photos of the scratch were taken at different time points (3-6-24-27-30-
48 hours) and analysed to find out the optimal time period of migration (Figure 
4-13). There was no change observed in the first six hours but a day later, up to 
40% of the scratch was closed in HT29 cultures and nearly 70% in the case of 
HCT116 cells. Later time points did not show any big migration activities and 
hence were excluded for further experiments.  
Figure 4-12 scratch closure tested in HT29 cells in two different cell densities 
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4.4.2 Migration behaviour of cells to close the scratch 
Based on the established protocol, scratch assays were performed with different 
approaches.  
Migration of the cell lines HCT116 and HT29 into the “wound” is depicted in Fig-
ure 4-14 with corresponding photos. The photos show a significant narrowing in 
the case of HCT116 while HT29 cells seem to be slower in migrating. Calculation 
of the ratio to the original width (Figure 4-14 right) shows a difference of about 20-
30% in 24 hours between the two cell lines.  
 
  
24h 
later 
HT29 
HCT116 
Figure 4-14 scratch results for the cell lines HCT116 and HT29: Left, photos of the original scratch and 
 24 hours later taken at 4x magnification; Right, plot of measured and calculated width closure 
****p < 10
-17 
Figure 4-13 percentage of scratch closure after several hours in HCT116 and HT29 cells 
**** 
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Figure 4-15 scratch assay results of left HCT116 and 
right HT29 cells stably overexpressing either the Arg or Gly allele of FGFR4 
bars represent ±SD; asterisks on columns represent significance to control; *p < 1.0 
Transfected cell lines were observed (Figure 4-15) and data normalized to 
pcDNA3-controls. It emerged that the FGFR4gly cells were less able to close the 
scratch at the given time point than cells overexpressing the Arg allele, but still 
above 100% and thus better than the controls. Notably, the HT29 Gly cell line 
was about the same level or slightly lower than the control cell line (taken here as 
100%) pointing out a possible role of FGFR4gly.  
4.4.3 FGFR4 ligand stimulated migration 
Treatment of HT29 cells with different concentrations of FGF18 and FGF19 led to 
results shown in Figure 4-16. FGF18 did not change migration when compared to 
control.  
  
Figure 4-16 percentage of scratch closure at different concentrations of factor treatment in HT29 cells; 
Left FGF18 and right FGF19 
 
* 
* 
* 
* 
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By contrast, we could see an effect of FGF19 on the migration of untransfected 
HCT116 cells: as Figure 4-17 shows, increasing concentrations of FGF19 im-
paired the “wound healing” ability.  
The same approach was used for FGFR4 overexpressing HT29 and HCT116 
cells. Figure 4-18 shows results for the scratch closing ability of HCT116 trans-
fectants with FGF18 and FGF19 treatment.  
FGF19 significantly inhibited migration of FGFR4 overexpressing HCTs when 
compared to untreated controls (Figure 4-18). As in HT29 cells FGF18 caused 
hardly any difference, while FGF19 inhibited migration (Figure 4-19).  
 
  
Figure 4-17 effect of exogenous FGF19 to the scratch closing ability 
(migration) on HCT116 cells; bars represent ±SD; *p <1.0 
 
Figure 4-18 scratch closing results 
of stably FGFR4
arg
 or FGFR4
gly
 overexpressing HCT116 when 
stimulated with different concentrations of left FGF18 and right FGF19;  
asterisk on column represents significance to control, *p < 1.0 
* 
* 
* 
* 
* * 
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4.5 Invasive properties of cells 
4.5.1 Development of a protocol for invasion assay 
To determine the invasive properties of the cells, a new protocol was established 
using migration filters coated with ECM protein. HCT cells were chosen for opti-
misation experiments since they had the highest migration potential (see chapter 
4.4.2). Matrigel and collagen were tested in different concentrations for coating of 
migration filters (see Materials and Methods, chapter 3.5.3). Figure 4-20 shows 
photos of wells containing the cells that reached the lower chamber. Cells that 
had to invade Matrigel™ seem to have migrated as clusters and thicker Matrigel 
gels inhibited migration. When the reagent was diluted in twice the amount of 
PBS, significant numbers of cells reached the lower chamber (Figure 4-20 right 
picture set, lower panel 1:1 and pure). In the filters coated with collagen, cells 
were detected in the bottom of all wells, increasing with the collagen concentra-
tion. Collagen was therefore chosen for further experiments.  
Figure 4-20 results of the invasion assay test approach; used cells were HCT116 
Figure 4-19 scratch closing results of stably FGFR4
arg
 or FGFR4
gly
 overexpressing HT29  
when stimulated with different concentrations of FGF18  
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4.5.2 Invasion ability of FGFR4 overexpressing cells 
The invasive potential of FGFR4 overexpressing cell lines was tested for SW480 
and HCT116 transfectants. Either allele of FGFR4 improved the invasive ability of 
both cell lines (Figure 4-21). In both cell lines (HCT116 and SW480), FGFR4arg 
transfectants showed increased invasion: compared to control and Gly cells there 
is nearly 100% difference (Table 4-2). 
 
 
% of control ±SD 
FGFR4
arg
 FGFR4
gly
 
HCT116 240.6 ± 5.5% 162.5 ± 5.4% 
SW480 338.1 ± 2.0% 214.2 ± 15.7% 
 
Table 4-2 invasion values normalized to mean of pcDNA ±SD 
  
Arg Gly pcDNA 
H
C
T
1
1
6
 
SW
4
8
0
 
Figure 4-21 in-well pictures of stained SW480 and HCT116 FGFR4 overexpressing cells  
migrated through collagen layer (upper panel) 
plot of calculated percentage in the lower panel, values shown in Table 4-2 
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4.6 Signalling 
The state of the direct FGFR target FRS2 was checked using ELISA for three dif-
ferent cell lines. Two different antibody incubations were performed for 
phosphorylated and total FRS2 respectively (see chapter 3.7.6), and the fluores-
cence measured at appropriate wavelengths. Relative fluorescence units were 
defined and ratios of phospho/total FRS2 calculated. Finally, values were normal-
ized to the control cell line. 
FRS phosphorylation in SW480 cells was equal to or slightly above pcDNA-
controls while HT29 overexpressors displayed lower phosphorylation states. 
FGFR4 overexpressing HCT116 cells showed nearly 1.5 fold increase of FRS2 
phosphorylation. 
When comparing the two FGFR4 alleles, SW480gly cells had slightly more phos-
phorylated FRS2 than SW480arg while for HT29 and HCT116 there were no sig-
nificant differences.  
4.6.1 Downregulation of FGF18 
Using siRNA oligonucleotides, FGF18 was downregulated in the transfected 
SW480 cell lines. Efficiency was checked with RT-PCR analysis. RNA-
nucleotides (si-scrambled) were used for control. Figure 4-23 shows efficient 
downregulation of FGF18 mRNA with at least 80% less FGF18 mRNA than in 
scrambled controls. 
  
Figure 4-22 phosphorylation ratio in FGFR4 overexpressing 
SW480, HT29 and HCT116 cells, bars represent ±SD 
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Protein was isolated from the FGFR4 overexpressing and FGF18 downregulated 
SW480 cells (further referred as KD) which were either stimulated with FGF18 for 
5’/15’ (5’/15’ KD) or not stimulated (unstim. or FGF18-). Phosphorylation of direct 
(PLCγ) and indirect downstream targets (ERK, S6, Src, GSK3β) of FGFR4 were 
analysed using Western Blotting. Bands were semi-quantified and analysed with 
Photoshop. Quotient of total protein to the loading control (β-actin) of the control 
cell line was calculated. Phosphorylation ratio was normalized to that of the con-
trol cell line. 
 
  
Figure 4-23 siRNA transfection of FGFR4 overexpressing SW480 cells 
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FGF18 knockdown increased total PLCγ levels in Gly cells which could be partly 
reversed when treated with factor for 5’. FGFR4arg overexpressing cells did not 
display any significant change in the FRS2 levels with FGF18 downregulation. 
Phosphorylation of the direct FGFR4 target, PLCγ, was significantly decreased 
with FGF18 knockdown in FGFR4gly overexpressing cells. A rescue could be 
seen after 5 minutes of factor treatment which nevertheless fell back 10’ later. A 
similar effect was observed in controls with mostly endogenous FGF18. FGFR4arg 
transfectants were not affected significantly. 
 
 
Figure 4-24 upper panel pPLCγ/PLCγ bands for FGFR4
arg
 or FGFR4
gly
 overexpressing SW480 cells  
with knockdown (KD) and/or addition of FGF18 in a given time; scr refers to non-knockdown  
lower panel plots of quantified bands normalized to that of control cell line, bars represent ±SD 
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FGF18 knockdown did not significantly affect total Src levels – neither in 
FGFR4arg nor in FGFR4gly overexpressing cells.  
However, Src activation via phosphorylation was reduced in FGF18 downregulat-
ed Gly cells which could be rescued by FGF18 treatment. There were no 
changes detected in total Src levels of Arg cells. 
  
Figure 4-25 upper panel pSrc/Src bands for FGFR4arg or FGFR4gly overexpressing SW480 cells 
with knockdown (KD) and/or addition of FGF18 in a given time; scr refers to non-knockdown  
lower panel plots of quantified bands normalized to that of control cell line, bars represent ±SD  
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Ratio of total ERK protein to the pcDNA control group revealed a downregulation 
of ERK with FGF18 knockdown in both FGFR4arg and FGFR4gly overexpressing 
cells. Exogenous factor treatment for 5’ partly rescued this phenotype. 
ERK protein phosphorylation was slightly increased by FGF18 downregulation in 
SW480arg cells which were reversed by addition of exogenous FGF18. In non-
knockdown controls, factor treatment for 5’ lowered phosphorylation of ERK. 
ERK activation of FGFRgly overexpressing cells was not affected by FGF18 
mRNA reduction.  
 
  
Figure 4-26 upper panel pERK/ERK bands for FGFR4
arg
 or FGFR4
gly
 overexpressing SW480 cells  
with knockdown (KD) and/or addition of FGF18 in a given time; scr refers to non-knockdown 
lower panel plots of quantified bands normalized to that of control cell line, bars represent ±SD 
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FGF18 downregulation led to reduced total GSK levels in both FGFR4 overex-
pressors but could be rescued by factor addition and incubation for 5 minutes in 
Arg overexpressors. 15’ stimulation with factor decreased GSK levels further and 
a similar effect could be observed in non-knockdown cells treated for 5’. 
GSK phosphorylation levels were slightly downregulated in Arg KD cells. In con-
trast, FGFRgly overexpressing cells displayed an increase in the GSK 
phosphorylation level with FGF18 knockdown. This could be partly rescued with 
treatment of exogenous factor for 15 minutes. 
  
Figure 4-27 upper panel pGSK/GSK bands for FGFR4arg or FGFR4gly overexpressing SW480 cells  
with knockdown (KD) and/or addition of FGF18 in a given time; scr refers to non-knockdown 
lower panel plots of quantified bands normalized to that of control cell line, bars represent ±SD 
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Total S6 levels were strongly reduced by knockdown of FGF18 in FGFR4arg 
overexpressing cells and a response to factor addition was not seen. In Gly cells 
a slight decrease was observed which was stronger when FGF18 was adminis-
tered. 
S6 activation was reduced with FGF18 knockdown in both FGFR4 overexpress-
ing cells. Additional FGF18 did not rescue this and even lowered levels in 
scrambled controls when treated for 5’. 
  
Figure 4-28 upper panel pS6/S6 bands for FGFR4arg or FGFR4gly overexpressing SW480 cells with  
knockdown (KD) and/or addition of FGF18 in a given time; scr refers to non-knockdown 
lower panel plots of quantified bands normalized to that of control cell line, bars represent ±SD 
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5 Discussion 
FGFR4 is a member of the fibroblast growth receptor family and plays an essen-
tial role in proliferation, differentiation and survival. In cancers of the breast, 
prostate and muscles (rhabdomyosarcoma) a pro-oncogenic role has been de-
scribed (Ye et al. 2011, Taylor et al. 2009, Roidl et al. 2009, Wang et al. 2008, 
Sahadevan et al. 2007, Jaakkola et al. 1993). 
Especially the G388R polymorphism was shown to increase tumour risk and de-
crease survival rate in many cancer types (Frullanti et al. 2011). Wang and his 
colleagues (2008) suggested a mechanism that increases FGFR4 stability and 
leads to prolonged signalling.  
How this polymorphism acts, which intracellular signalling pathways are involved 
and what role it plays in CRC development in vivo and in vitro is not elucidated. 
Here, we observed malignant characteristics like growth, migration and adhesion 
in FGFR4 overexpressing CRC cell lines and tried to determine intracellular alter-
ations with or without the FGFR4 ligand FGF18 which was defined as a pro-
tumorigenic and pro-metastatic factor (Sonvilla et al. 2008). 
5.1 FGFR4 ligand expression in colon cancer cell lines and in FGFR4 
overexpressing cells 
Expression of the FGFR4 ligands FGF18 and FGF19 was analysed because both 
ligands could cause autocrine stimulation loops with FGFR4 (Zhang et al. 2006).  
FGF19 levels were high in two cell lines at progressed tumour stages (HCT116 
and SW620), suggesting a possible increase of FGF19 expression with the tu-
mour stage. Also in the cell line Colo-201 FGF19 expression was about 6-fold to 
that of SW480 (not shown, C. Heinzle found 16-fold expression). This also fits 
with the work of Desnoyers et al. (2008) who described autocrine stimulation of 
CRC cells by FGF19. These 3 cell lines were found to express more FGFR4 than 
SW480 do, with HCT116 and SW620 being FGFR4gly homozygous and Colo-201 
cells expressing both alleles (C. Heinzle thesis 2011). Desnoyers et al. (2008) 
used a specific anti-FGF19 monoclonal antibody and achieved growth inhibition 
of colon tumour xenografts in vivo.  FGF19 could specifically act on FGFR4gly and 
mediate growth.  
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FGF18 level was the highest in the SW620 cells (a cell line obtained from a tu-
mour tissue at lympho-invasive stage), while adenoma cells showed no 
detectable expression, correlating with the data of Sonvilla et al. (2008).  
C. Heinzle showed highest FGF18 expression in SW480 cells, followed by Caco-
2, SW620 and LT97-2 (thesis 2011).  Transfection with FGFR4 expression vec-
tors seems to have a negative effect on FGF18 levels when compared to 
pcDNA3-control. There was no FGF19 mRNA expression detected in the trans-
fectants suggesting a negative feedback loop. 
5.2 FGFR4 overexpression in colon cancer cell lines 
The cell lines HT29 and SW480 were transfected with FGFR4 overexpressing 
vectors and expression was checked. Overall, FGFR4 overexpression could be 
determined on high levels in both cell types. 
On the transcriptional and translational levels, two to four fold expression above 
the control could be achieved in SW480s. FGFR4arg overexpressing SW480 cells 
showed higher expression levels than FGFR4gly transfectants in both RNA and 
protein, suggesting a higher stability and stronger signalling of the Arg variant.  
In heterozygous HT29s, the Gly transfectants showed higher expression than Arg 
cells.  
Allelotypic analysis of HT29 transfectants revealed that the control cells showed 
mostly FGFR4arg overexpression with an Arg/Gly ratio of 6:1. In HT29arg the Arg 
allele was clearly the majority of all expressed FGFR4 RNA molecules while in 
HT29gly cells the Arg allele was still expressed, associating with the dominance of 
the Arg allele, but the 3-fold amount of RNA from the transfected Gly allele was 
also detected. Similar results were obtained by C. Heinzle in FGFR4 overex-
pressing HCT116 and SW480 cells (see C. Heinzle thesis 2011). 
5.3 EMT markers Fibronectin and Vimentin 
Expression of the two EMT markers fibronectin and vimentin was checked in 
HT29 and SW480 cells using fluorescent antibody. Fibronectin is a mesenchymal 
marker and can be found in the extracellular matrix. High fibronectin expression 
was correlated with progressed tumour stage (Saito et al. 2008) and node-
positive CRC formation (Meeh et al. 2009). Vimentin is a cytoskeletal protein (in-
termediate filament) that is expressed in mesenchymal cells. 
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In HT29 cells baseline levels for both markers were low and FGFR4 overexpres-
sion increased immunodetectable protein in both cases. For the Gly allele this 
effect was stronger than for the Arg allele. By contrast, SW480 untransfected and 
control cells expressed high levels of both fibronectin and vimentin. FGFR4 over-
expression in these cells had little impact on the mesenchymal markers. Only 
FGFR4gly transfectants had slightly increased marker staining.  
This suggests that FGFR4arg and FGFR4gly have different influence on the ex-
pression of these EMT markers. These results need to be reconciled with the 
observation that FGFR4arg transfectants display higher migration and metastatic 
activity which is usually related to EMT (Thiery 2002). 
5.4 FGFR4arg improves viability 
Cell growth was not particularly affected through FGFR4 but a slight improvement 
was detected in FGFR4arg overexpressing SW480 cells cultured in starvation me-
dium without factors. We could not detect any growth supporting effects by 
FGF19 on SW480 cells or FGF18 on HT29 cells. This contradicts reports from 
Pai et al. (2008) who used FGF19 to promote of HT29 and Colo-201 cells through 
activation of the Wnt signalling pathway (increased activation of β-catenin). How-
ever, they used five- to ten-fold more FGF19 than we did. The difference between 
these results and our own data need to be further explored. 
5.5 Effects on migration, invasion and adherence 
The FGFR4 polymorphism affected migration and adhesion in HT29 (data not 
shown), HCT116 and SW480 cells: cells overexpressing the Gly allele adhered 
better and were able to form more colonies while the Arg allele rather contributed 
to migration and invasion. This was also confirmed by C. Heinzle’s work (see the-
sis 2011) and is in line with the findings of Bange et al. (2002) associating the 
FGFR4arg allele with early lymph node and advanced tumour-node metastasis. 
FGFR4arg was shown to interact and stabilise membrane-type 1 matrix metallo-
proteinase (MT-MMP-1) and support collagen invasion (Sugiyama et al. 2010*, 
Sugiyama et al. 2010). 
FGF19 administration improved attachment of FGFR4 overexpressing SW480 
cells but impaired migration in HCT116 – both transfected and untransfected. 
How this relates to the results described by Pai and his colleagues (2008) is not 
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yet understood because the role of Wnt-signalling on the migration and adhesion 
of CRC cells is still unknown. 
SW480 cells express more FGF18 than FGF19 (see chapter 4.1.1) which could 
act negatively on FGFR4arg and impair attachment that is then restored by FGF19 
administration. 
In HCT116 cells, FGF18 expression is lower when compared to the SW480s but 
FGF5 expression levels were similar to FGF19 levels (C. Heinzle thesis 2011). 
Therefore, FGF19 may inhibit FGF5 activity through blocking the receptors und 
thus impair its effects on migration. FGF5 is a key player in the hair follicle growth 
cycle and takes part in myogenesis (Beenken and Mohammadi 2009). Whether it 
is involved in migration processes of CRC (or in general cancer) cells would be a 
new discovery. Thus, these findings infer a novel role for FGF19 (and maybe 
FGF5) in malignant behaviour and need further investigation. 
5.6 Development of the Invasion assay and obtained results 
An invasion assay protocol was developed using collagen and Matrigel™ to coat 
membrane filters. This provides not only an obstacle for invasion but also ECM 
contacts that are usually absent from the 2D in vitro assays we routinely used in 
this study. Surprisingly, the more collagen was deposited on the filter membrane, 
the more cells were able to invade, indicating that interaction with the matrix pro-
tein stimulates invasion. In a recent paper, Spivey et al. (2011) could positively 
link collagen (type XXIII) to metastasis through cell-cell and cell-ECM adhesion. 
Cell-matrix interaction was even more obvious when using Matrigel™ as this 
hanged cell behaviour. The tumour cells formed clusters and increasing concen-
trations of Matrigel™ inhibited invasion. 
5.7 Signalling effects and influence of FGF18 downregulation 
FRS2 levels were analysed in three different CRC cell lines, overexpressing ei-
ther Arg or Gly allele of FGFR4 and compared to the control cell line (pcDNA). No 
significant differences were found between the two alleles. Compared to control, 
phosphorylation of FRS2 was high in HCT116, equal in SW480 but lower in HT29 
cells. This shows that FGFR4 acts differently depending on the cell line and 
seems to have more influence on the signalling of progressed colorectal tumour 
cell lines. It is consistent with better migration of HCT116 cells which seems to be 
mediated by endogenous FGF19 interaction, probably through FRS2 and Src 
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(Lieu and Kopetz 2010). FGF19 was inhibition was previously described to re-
duce FRS2 and ERK2 phosphorylation along with active β-catenin levels (Pai et 
al. 2008). 
 PLCγ Src ERK GSK3β S6 
FGFR4
arg
 
↔phospho 
↔total 
↔phospho 
↓total 
↔phospho 
↓total 
↔phospho 
↓total 
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↓total 
FGFR4
gly ↓phospho 
↑total 
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↔total 
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↓total 
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↓total 
↔phospho 
↓total 
Table 5-1 intracellular effect of FGF18 knockdown on FGFR4 overexpressing SW480 cells 
↑ up- and ↓ downregulation or ↔ unchanged, strong effects in bold 
 
 t PLCγ Src ERK GSK3β S6 
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arg
 
5’ 
15’ 
↔ ↑p ↑total ↓p ↑total 
↑p ↓total 
↔ 
↔ 
FGFR4
gly 5’ 
15’ 
↑p ↓total 
↔ 
↑p  
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↔ 
↔ 
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Table 5-2 intracellular effect of exogenous FGF18 on FGFR4 overexpressing cells  
t refers to incubation time, p to phosphorylated protein 
↑ up- and ↓ downregulation or ↔ unchanged, strong effects in bold 
 
FGF18 knockdown downregulated phosphorylation of PLCγ and Src, while it up-
regulated phosphorylation of GSK3ß in SW480gly cells, but did not affect 
phosphorylation status of signalling proteins in SW480arg (Table 5-1). Addition of 
exogenous FGF18 reversed the KD-effects in SW480gly. In SW480arg cells it in-
creased phosphorylation of Src and GSK3ß, but downregulated pERK. 
Interestingly, PLCγ was only affected in Gly but not in Arg-transfectants. 
PLCγ is a direct target of FGFR4 and through PKC activation via DAG, is in-
volved in cell growth, differentiation and migration (Suh et al. 2008). Stable 
silencing of PLCγ was reported to have anti-tumorigenic effects on CRC cells 
(Tan et al. 2007). FGF18 downregulation slightly decreased phosphorylated but 
strongly increased total PLCγ in SW480gly cells but did not affect FGFR4arg over-
expressing cells. Treatment with factor for 5’ reversed these effects. FGFR4 
G388 was reported to inhibit motility and invasion of a type of breast cancer cells 
by suppression of specific genes involved in these processes (Stadler et al. 2006). 
Knockdown resulted in enhanced invasion through MT1-MMP (Sugiyama et al. 
Discussion 
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2010*). PLC signalling has been shown to modulate PI-3K dependent cell motility 
(Kolsch et al. 2008). Whether general FGF dependent modulation of PLC activity 
plays a role in this context needs to be determined. 
Src is a kinase and interacts with PLCγ in tumour cells (Suh et al. 2008, Tvorogov 
et al. 2005). It is crucial for activation and termination of FGFR signalling 
(Sandilands et al. 2007). It can affect survival through regulation of PI-3K-Akt 
pathway, proliferation through the MAPK pathway, angiogenesis by STAT3/5b 
and motility as well as invasion (Lieu and Kopetz 2010). N-Cam was found to in-
duce FGFR1 stabilisation and recycling leading to Src mediated cell migration 
(Francavilla et al. 2009). Phosphorylation was decreased in FGF18 knocked 
down SW480gly protein lysates while in SW480arg cells Src protein level was 
slightly downregulated. FGF18 administration rescued both effects. This gives 
FGF18 a role in the mobility of cells through the Gly allele while the FGFR4arg 
may facilitate independence from the FGF18 and thus from Src signalling. 
ERK is a downstream component of the MAPK signalling pathway (chapter 
1.7.2.1) and was found to be downregulated with FGF18 knockdown in SW480arg 
as well as in SW480gly cells. While factor addition rescued these phenotypes in 
SW480arg cells and even down-regulated ERK phosphorylation, this effect was 
only transient in SW480gly cells. Sonvilla et al. (2008) already reported of the pro-
tumorigenic effect of FGF18. Here, the Arg allele may render the receptor more 
sensitive to FGF18, leading to a long-lasting pro-proliferative effect through acti-
vation of the MAPK pathway.  
Glycogen synthase kinase 3β protein level was also decreased in SW480arg and 
SW480gly cells treated with si-FGF18 with an increase of pGSK3β level in the lat-
ter. Downregulation of total GSK3β was with the consequence of factor addition 
for 5’ in SW480arg cells. Interestingly SW480gly cells responded 10’ later with an 
upregulation of the pGSK3β level while total protein was further decreased. As 
discussed earlier, this kinase plays a role in the degradation of β-catenin. Since 
FGF18 is a target gene of β-catenin (Katoh and Katoh 2006*, Shimokawa et al. 
2003), it could be crucial to suppress inhibition of GSK3β, resulting in an auto-
inhibition. Response to FGF18 treatment in the later time point and rescue ind i-
cates that the FGFR4gly may act through a different pathway in the absence of 
FGF18.  
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Not phosphorylated, active GSK3β negatively regulates SNAIL activity which then 
cannot repress E-cadherin transcription (Katoh and Katoh 2006). In our im-
munostaining experiment, we showed upregulation of the mesenchymal markers 
fibronectin and vimentin in FGFR4gly overexpressing SW480 cells. FGF18 seems 
to decrease GSK3β activity through decreasing total GSK3β and/or increasing 
deactivation through phosphorylation and further be responsible for the mesen-
chymal polarisation of especially the SW480gly cells. 
S6 or S6 kinase (S6K) is a component of the ribosomal subunit 40S and known to 
play a role in the regulation of proliferation, protein translation, survival and tu-
mour growth. Its activation is regulated through mTORC1 and PDK1 that lies 
downstream of the PI-3K-Akt pathway (Fenton and Gout 2011). Knockdown of 
FGF18 decreased total S6 levels in SW480arg cells and also in FGFR4gly overex-
pressing cells. FGF18 administration did not change anything in SW480arg cells 
but had a further negative effect on the FGFR4gly transfectants. 
5.8 Conclusions 
Our results indicate a role for FGFR4 G388R polymorphism in tumour progres-
sion and motility of cells. FGFR4 seems to be an oncogene with the Gly allele 
responsible for attachment, colony formation in vitro and malignant growth in vivo 
(C. Heinzle thesis 2011) while Arg stimulates invasiveness and acts strongly pro-
metastatic (also in tissues – C.Heinzle diss. 2011). 
Structural alterations have to exist since intracellular signal transduction differed 
depending on the overexpression of FGFR4 alleles and the ligand. It seems that 
FGFR4 R388 variant shifts intracellular signalling to mainly the MAPK pathway.  
Further investigations are required to resolve remaining inconsistencies regarding 
results from ligand stimulated cells. Studies will be pursued also in 3D culturing to 
simulate in vivo environment.
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7 Abstract 
The FGF-FGFR system consists of 22 ligands and various receptors expressed from four 
FGFR genes that play important roles in survival, migration and neo-angiogenesis. Can-
cer cells deregulate and exploit this system by various mechanisms including 
overexpression of FGFs and FGFRs and autocrine stimulation of tumour cells. This leads 
to sustained signalling resulting in tumour cell growth and cancer progression. Specifical-
ly FGFR4 is involved in tumour aggressiveness in several tumour types. A single 
nucleotide polymorphism (G388R) in the transmembrane domain was described with the 
presence of FGFR4 Arg allele leading to enhanced metastasis.  
We investigated (1) the biological role of the FGFR4 polymorphism in colorectal cancer 
cells and (2) the differential activation of the polymorphic alleles by the ligands FGF18 
and FGF19. The results of this study demonstrate higher aggressiveness of FGFR4arg 
cells which could also be confirmed through investigation of the invasion activity espe-
cially in HCT116 cells. Cells expressing mostly FGFR4gly displayed an increased 
attachment and colony formation ability. In contrast, expression of mesenchymal markers 
was quite low in FGFR4arg overexpressing SW480 cells and also the FGFR4arg express-
ing HT29 cells while overexpression of the Gly allele enhanced mesenchymal markers. 
Addition of FGF18 and FGF19 to cell culture medium did not stimulate growth and 
clonogenicity. FGF19 inhibited cell migration and increased cell attachment independent 
of FGFR4 allele.  
FGF18 knockdown downregulated phosphorylation of PLCγ and Src, while it upregulated 
phosphorylation of GSK3ß in SW480gly cells, but did not affect phosphorylation status of 
signalling proteins in SW480arg. Addition of exogenous FGF18 reversed the KD-effects in 
SW480gly. In SW480arg cells it increased phosphorylation of Src and GSK3ß, but down-
regulated pERK. These observations indicate FGF18 signalling FGFR4, especially the 
Gly allele. Mechanistic details still need to be elucidated. 
In summary, our observations suggest that autocrine stimulation by FGF18 and FGF19 
via FGFR4 is a player in tumour growth and progression that needs to be further eluci-
dated. 
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8 Zusammenfassung 
Das FGF-FGFR System besteht aus 22 Liganden und 4 Rezeptoren die eine wichtige 
Rolle für das Überleben, die Migration und Neo-Angiogenese spielen. In Krebszellen ist 
dieses System u. A. durch Überexpression von FGFs und deren Rezeptoren dereguliert. 
Das führt durch autokrine Stimulation zu einer anhaltenden Signalaktivität, die das Tu-
morzellwachstum fördert und zur Krebsprogression beiträgt. Speziell FGFR4 wurde mit 
Tumoraggressivität in verschiedenen Tumortypen assoziiert. Ein Polymorphismus wurde 
beschrieben, der das Gly an der Stelle 388 der FGFR4 Transmembrandomäne durch ein 
Arg ersetzt was die Metastasierung fördert. 
Wir untersuchten (1) die biologische Rolle dieses Polymorphismus in kolorektalen Karzi-
nom-Zellen und (2) die unterschiedliche Aktivierung der Genprodukte der Allel durch die 
Liganden FGF18 und FGF19. Die Ergebnisse dieser Studie zeigen höhere Aggressivität 
von FGFR4arg Zellen, die auch durch Invasionsdaten besonders in HCT116 Zellen bestä-
tigt wurden. Zellen, die hauptsächlich FGFR4gly exprimieren, wiesen erhöhte 
Anheftungsfähigkeit und verbesserte Kolonienbildung auf. Expression von mesenchyma-
len Markern hingegen, war niedrig in SW480 FGFR4arg Transfektanten wie auch in den 
FGFR4arg heterozygoten HT29 Zellen, während Überexpression eines Gly Allels die Ex-
pression der mesenchymalen Marker förderte.  
Zugabe von FGF18 und FGF19 in das Medium hatte keinen Effekt auf das Wachstum 
und die Kolonienbildung. FGF19 inhibierte Zellmigration und erhöhte Zellanheftung un-
abhängig vom FGFR4 Allel. 
Herunterregulation von endogenem FGF18 wirkte sich negativ auf die Phosphorylierung 
von PLCγ und Src aus, erhöhte aber GSK3ß Phosphorylierung in SW480gly Zellen 
während in SW480arg Zellen der Phosphorylierungsstatus von Signalproteinen unberührt 
blieb. Zugabe von exogenem FGF18 konnte die Knockdown-Effekte in SW480gly auf-
heben. In SW480arg Zellen erhöhte FGF18-Zugabe Phosphorylierung von Src und 
GSK3ß aber pERK Level wurde erniedrigt. Diese Beobachtungen deuten auf eine 
FGF18 Signalwirkung durch FGFR4, besonders dem Gly Allel.  
Unsere Studie weist auf die Möglichkeit einer autokrinen Stimulation von Tumorzellen 
durch FGF18 und FGF19 hin, die durch den FGF Rezeptor 4 vermittelt wird. 
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„Establishment of a FACS protocol for macrophage 
polarization” 
„Role of heme oxygenase 1 (HO-1) in macrophages in 
the context of type 2 diabetes mellitus” 
Praktikum bei Prof. Brigitte Marian (Cellular and 
Molecular Tumorbiology, Institut f. Krebsforschung) 
„FGF-Rezeptor 4 Allele in der Darmkrebs-Zelllinie 
HT29“ 
Praktikum bei Prof. Manuela Baccarini (Max F. Perutz 
laboratories, Universität Wien) 
„Role of c-raf and rassf1A in liver cancer in mice” 
„Influence of c-raf and rassf1a ablation on MAPK and 
MST signalling in HCC” 
 
